WO2007053455A2 - Ligands polypeptidiques pour recepteur de type toll 4 (tlr4) - Google Patents

Ligands polypeptidiques pour recepteur de type toll 4 (tlr4) Download PDF

Info

Publication number
WO2007053455A2
WO2007053455A2 PCT/US2006/042051 US2006042051W WO2007053455A2 WO 2007053455 A2 WO2007053455 A2 WO 2007053455A2 US 2006042051 W US2006042051 W US 2006042051W WO 2007053455 A2 WO2007053455 A2 WO 2007053455A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
tlr4
idno
seqidno
polypeptide
Prior art date
Application number
PCT/US2006/042051
Other languages
English (en)
Other versions
WO2007053455A3 (fr
Inventor
Valerie Odegard
Thomas J. Powell
Original Assignee
Vaxinnate Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxinnate Corporation filed Critical Vaxinnate Corporation
Publication of WO2007053455A2 publication Critical patent/WO2007053455A2/fr
Publication of WO2007053455A3 publication Critical patent/WO2007053455A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Definitions

  • TLR4 Receptor 4
  • the novel polypeptide ligands modulate TLR4 signaling and thereby regulate the Innate Immune Response.
  • the invention provides methods of modulating TLR4 signaling using the polypeptide TLR4 ligands of the invention.
  • the invention also provides vaccines comprising the novel polypeptide TLR4 ligands and an antigen.
  • the invention further provides methods to stimulate an immune response using the polypeptide TLR4 ligands and vaccines of the invention.
  • Multicellular organisms have developed two general systems of immunity to infectious agents.
  • the two systems are innate or natural immunity
  • innate immunity innate immunity
  • adaptive adaptive or specific
  • the innate immune system uses a set of germline-encoded receptors for the recognition of conserved molecular patterns present in microorganisms. These molecular patterns occur in certain constituents of microorganisms including: lipopolysaccharides, peptidoglycans, lipoteichoic acids, phosphatidyl cholines, bacterial proteins, including lipoproteins, bacterial DNAs, viral single and double- stranded RNAs, unmethylated CpG-DNAs, mannans, and a variety of other bacterial and fungal cell wall components. Such molecular patterns can also occur in other molecules such as plant alkaloids.
  • PAMPs Pathogen Associated Molecular Patterns
  • PRRs Pattern Recognition Receptors
  • CD14, DEC205, collectins Some of these receptors recognize PAMPs directly ⁇ e.g., CD14, DEC205, collectins), while others (e.g., complement receptors) recognize the products generated by PAMP recognition.
  • Cellular PRRs are expressed on effector cells of the innate immune system, including cells that function as professional antigen-presenting cells (APC) in adaptive immunity.
  • APC professional antigen-presenting cells
  • effector cells include, but are not limited to, macrophages, dendritic cells, B lymphocytes, and epithelial cells.
  • This expression profile allows PRRs to directly induce innate effector mechanisms, and also to alert the host organism to the presence of infectious agents by inducing the expression of a set of endogenous signals, such as inflammatory cytokines and chemokines. This latter function allows efficient mobilization of effector forces to combat the invaders.
  • TLRs Toll-like receptors
  • TLRs 1 through 11 and TLR13 have been identified to date (see, for example, Medzhitov et al Nature 1997;388:394- 397; Rock et al Proc Natl Acad Sci USA 1998;95:588-593; Takeuchi et al Gene 1999;231 :59-65; and Chuang and Ulevitch. Biochim Biophys Acta. 2001;1518:157- 61). In mammalian organisms, such TLRs have been shown to recognize
  • PAMPs such as the bacterial products LPS (Schwandner et al. J. Biol. Chem. 1999;274: 17406-9 and Hoshino et al J. Immunol 1999;162:3749-3752), lipoteichoic acid (Schwandner et al J. Biol. Chem. 1999;274: 17406-9), peptidoglycan (Yoshimura et al J. Immunol. 1999; 163: 1-5), lipoprotein (Aliprantis et al Science 1999;285:736- 9), CpG-DNA (Hemmi et al. Nature 2000;408:740-745) 3 and flagellin (Hayashi et al.
  • TLR2 is essential for the recognition of a variety of PAMPs, including bacterial lipoproteins, peptidoglycan, and lipoteichoic acids.
  • TLR3 is implicated in virus-derived double-stranded RNA.
  • TLR4 is predominantly activated by lipopolysaccharide.
  • TLR5 detects bacterial flagellin and TLR9 is required for response to unmethylated CpG DNA.
  • TLR7 and TLR8 have been shown to recognize small synthetic antiviral molecules (Jurk M. et al Nat Immunol 2002;3:499).
  • TLRs require the presence of a co- receptor to initiate the signaling cascade.
  • TLR4 which interacts with MD2 and CD 14, a protein that exists both in soluble form and as a GPI-anchored protein, to induce NF- ⁇ B in response to LPS stimulation (Takeuchi and Akira. Microbes Infect 2002;4:887-95).
  • Figure 1 illustrates some of the known interactions between PAMPs and TLRs (reviewed in Janeway and Medzhitov. Annu Rev Immunol 2002;20: 197-216).
  • TLR4 the first human TLR identified, is involved in the recognition of, for example, products of Gram negative bacteria such as lipopolysaccharide (LPS), products of Gram positive bacteria such as lipoteichoic acid, and the F protein of Respiratory Syncytial Virus (RSV F protein) (reviewed in Janeway and Medzhitov. Annu Rev Immunol 2002;20: 197-216).
  • LPS lipopolysaccharide
  • RSV F protein Respiratory Syncytial Virus
  • the envelope protein of Mouse Mammary Tumor Virus (MMTV env protein) has been shown to activate B-cells via TLR4 (Rassa et al. Proc Natl Acad Sci USA 2002;99:2281-2286).
  • Tlr4 The Tlr4 gene is mutated in C3H/HeJ and C57BL/1 OScCr mice, both of which are low responders to LPS (Poltorak et al Science 1998;282:2085-2088).
  • TLR4 requires the presence of accessory molecules to initiate the signaling cascade.
  • TLR4 interacts with MD2 and CD 14, a protein that exists both in soluble form and as a GPI- anchored protein, to induce NF- ⁇ B in response to LPS stimulation (Shimazu et al. J Exp Med 1999;189:1777-1782 and Takeuchi and Akira. Microbes Infect 2002;4:887- 95).
  • TLR4 is known to homodimerize in a multisubunit cell surface protein complex containing two monomers of TLR4, a MD2 monomer, and a CD 14 monomer.
  • TLR4 signaling is mediated through the adapter protein MyD88 but also through a MyD88- independent pathway that involves the TIR domain containing adapter protein (TIRAP) (Homg e/ ⁇ /. Nat Immunol 2001;2:835-41).
  • TIRAP TIR domain containing adapter protein
  • TLR4 can induce the secretion of tumor necrosis factor (TNF) and of the interleukins IL-I and IL-6 as part of an antibacterial response, and can induce the secretion of the interferons INF ⁇ and INF ⁇ as part of an antiviral response.
  • TNF tumor necrosis factor
  • TLRs The intracellular signaling pathways initiated by activated TLRs vary slightly from TLR to TLR, with some signaling pathways being common to all TLRs (shared pathways), and some being specific to particular TLRs (specific pathways).
  • the cytoplasmic adaptor proteins myeloid differentiation factor 88 (MyD88) and TOLLIP (Toll-interacting protein) independently associate with the cytoplasmic tail of the TLR.
  • MyD88 myeloid differentiation factor 88
  • TOLLIP Toll-interacting protein
  • TAK-I leads, via one or more intermediate steps, to the activation of the IKB kinase (IKK), whose activity directs the degradation of IKB and the activation of NF- ⁇ B.
  • IKK IKB kinase
  • MKK6 leads to the activation of JNK (c-Jun N-terminal kinase) and the MAP kinase p38 (Medzhitov and Janeway. Trends in Microbiology 2000;8:452-456 and Medzhitov. Nature Reviews 2001;1 :135-145).
  • cytoplasmic proteins implicated in TLR signaling include the RHO family GTPase RACl and protein kinase B (PKB), as well as the adapter protein TIRAP and its associated proteins protein kinase PKR and the PKR regulatory proteins PACT and p58 (Medzhitov. Nature Reviews 2001 ; 1 : 135- 145). Cytoplasmic proteins specifically implicated in TLR-signaling by mutational studies include MyD88 (Schnare et al. Nature Immunol 2001;2:947-950), TIRAP (Horng et al.
  • TLR2 and TLR4 activate different immunological programs in human and murine cells, manifested in divergent patterns of cytokine expression (Hirschfeld et al. Infect Immun 2001;69:1477-1482 and Re and Strominger. J Biol Chem 2001;276:37692- 37699). These divergent phenotypes could be detected in an antigen-specific response, when lipopolysaccharides that signal through TLR2 or TLR4 were used to guide the response (Pulendran et al. J Immun 2001;167:5067-5076).
  • TLR4 and TLR2 signaling requires the adaptor TIRAP/Mal, which is involved in the MyD88-dependent pathway (Horng et al. Nature 2002;420:329-33).
  • TLR3 triggers the production of IFN ⁇ in response to double-stranded RNA, in an MyD88-independent manner. This response is mediated by the adaptor TRIF/TICAM-1 (Yamamoto et al. J Immunol. 2002; 169:6668-72).
  • TRAM/TICAM2 is another adaptor molecule involved in the MyD 88 -independent pathway (Miyake. InI Immunopharmacol. 2003;3.T 19-28) which function is restricted to the TLR4 pathway (Yamamoto et al. Nat Immunol.
  • TLR switching on different immune response "circuits", where activation of a particular TLR determines the type of antigen- specific response that is triggered.
  • the profile of cytokines produced and secreted can vary. This variation in TLR signaling response can influence, for example, whether the resultant adaptive immune response will be predominantly T- cell- or B-cell-mediated, as well as the degree of inflammation accompanying the response.
  • TLR Toll-like receptor
  • antigen fusion proteins a) induces antigen-specific T-cell and B-cell responses comparable to those induced by the use of conventional adjuvant, b) results in significantly reduced non-specific inflammation; and c) results in CD8 + T-cell- mediated protection that is specific for the fused antigen epitopes (see, for example US published patent applications 2002/0061312 and 2003/0232055 to Medzhitov, and US published patent application 2003/0175287 to Medzhitov and Kopp, all incorporated herein by reference).
  • mice immunized with a fusion protein consisting of the polypeptide PAMP BLP linked to Leishmania major antigens mounted a Type 1 immune response characterized by antigen-induced production of ⁇ -interferon and antigen-specific IgG 23 (Cote-Sierra ⁇ t al. Infect Immun 2002;70:240-248).
  • the response was protective, as demonstrated in experiments in which immunized mice developed smaller lesions than control mice did following challenge with live L. major.
  • a vaccine design should ensure that every cell that is exposed to pathogen-derived antigen also receives a TLR receptor innate immune signal and vice versa. This can be effectively achieved by designing the vaccine to contain a chimeric macromolecule of antigen plus PAMP, e.g., a fusion protein of PAMP and antigen(s). Such molecules trigger signal transduction pathways in their target cells that result in the display of co- stimulatory molecules on the cell surface, as well as antigenic peptide in the context of major histocompatability context molecules.
  • TLR-specific polypeptide ligands can be incorporated into TLR- ligand: antigen conjugate vaccines, whereby the TLR-ligand will provide for an enhanced antigen-specific immune response as regulated by signaling through a particular TLR.
  • the present invention relates to novel polypeptide ligands for Toll-like receptor 4 (TLR4). These novel polypeptide ligands modulate TLR4 signaling. These polypeptide TLR4 ligands may be incorporated into novel polypeptide TLR4 ligand-.antigen vaccines or may be used alone as immunomodulatory agents (e.g., agonists or antagonists).
  • TLR4 Toll-like receptor 4
  • the invention is directed, at least in part, to a polypeptide TLR4 ligand comprising at least one amino acid sequence selected from the group consisting of:
  • VKLSGS SEQ ID NO: 4
  • IVRGCLGW (SEQ ID NO: 7),
  • VSSAQEVRVP (SEQ ID NO: 45),
  • VEEYSSSGVS (SEQ ID NO: 47), and
  • VCEVSDSVMA (SEQ ID NO: 48).
  • the invention is also directed to a polypeptide TLR.4 Hgand comprising: i) at least one amino acid sequence selected from tl
  • VKLSGS SEQ ID NO: 4
  • IVRGCLGW (SEQ ID NO: 7),
  • VSSAQEVRVP (SEQ ID NO: 45),
  • VEEYSSSGVS (SEQ ID NO: 47), and
  • a TLR4 ligand of the invention contains at least one aromatic amino acid residue (Phe, Tyr or Tip).
  • the present invention also provides TLR4 ligands that are fragments of the above-mentioned ligands, and TLR4 ligands that are at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more homologous to the above- mentioned peptides, as well as derivates thereof, that bind to TLR4.
  • the invention is also directed to a polypeptide comprising: i) a polypeptide TLR4 ligand comprising at least one amino acid sequence selected from the group consisting of:
  • GGKSGRTG SEQ ID NO: 1
  • KGYDWLVVG SEQ ID NO: 2
  • EDMVYRIGVP SEQ ID NO: 3
  • VKLSGS SEQ ID NO: 4
  • GMLSLALF SEQ ID NO: 5
  • IVRGCLGW (SEQ ID NO: 7),
  • VSSAQEVRVP (SEQ ID NO: 45),
  • VEEYSSSGVS (SEQ ID NO: 47), and
  • the at least one polypeptide antigen is a pathogen-related antigen, a tumor-associated antigen, or an allergen-related antigen.
  • the pathogen-related antigen is an Influenza antigen, a Listeria monocytogenes antigen, a Flaviviridae antigen (including, but not limited to, West Nile virus, Japanese encephalitis virus, and Dengue virus), or a Hepatitis C virus antigen.
  • the invention is also directed a vaccine comprising at least one of the aforementioned polypeptides of the invention and, optionally, a pharmaceutically acceptable carrier.
  • the invention is further directed to a vaccine comprising: i) at least one polypeptide TLR4 ligand comprising at least one amino acid sequence selected from the group consisting of:
  • IVRGCLGW (SEQ IDNO: 7),
  • VSSAQEVRVP (SEQ ID NO: 45),
  • VEEYSSSGVS (SEQ ID NO: 47), and
  • the at least one polypeptide TLR4 ligand and the at least one antigen are covalently linked.
  • the at least one antigen is a polypeptide, a lipoprotein, a glycoprotein, a mucoprotein, a lipid, a saccharide, a lipopolysaccharide, or a nucleic acid.
  • the at least one antigen is a pathogen-related antigen, a tumor-associated antigen, or an allergen-related antigen.
  • the pathogen-related antigen is an Influenza antigen, a Listeria monocytogenes antigen, a Flaviviridae antigen (including, but not limited to, West Nile virus,
  • the invention is further direct to a method to stimulate an immune response in a subject comprising administering to a subject in need thereof one of the aforementioned polypeptides of the invention, or one of the aforementioned vaccines of the invention.
  • the subject is a mammal.
  • the invention is further directed to a method of modulating TLR4 signaling in a cell comprising contacting a cell, wherein the cell comprises TLR4, with a polypeptide TLR4 ligand comprising at least one amino acid sequence selected from the group consisting of:
  • VKLSGS SEQ ID NO: 4
  • IVRGCLGW (SEQ ID NO: 7),
  • KLCCFTECM (SEQ ID NO: 15), AVGSMERGRG (SEQ ID NO: 16),
  • the cell is a mammalian cell.
  • the cell is a mammalian cell.
  • the cell is a human cell and the TLR4 is a human TLR4.
  • Figure 1 depicts known interactions of PAMPs with various Toll-like Receptors (TLRs).
  • TLRs Toll-like Receptors
  • Figure 2 depicts an amino acid sequence alignment of amino acid sequences for human TLR4 (hTLR4) isoforms A (SEQ ID NO: 89), B (SEQ ID NO: 91), C (SEQ ID NO: 93), and D (SEQ ID NO: 95). "*" indicates that the amino acid residue at the indicated position is common to all four isoforms.
  • Figure 3 is a graph depicting secretion of interleukin 8 (IL-8, in pg/ml) by HEK293-nuU cells (Invivogen; cat. # 293-null) cells ("HEK293", - ⁇ -) versus HEK293:hTLR4A/MD2-CD14 cells ("HEK293:TLR4", - ⁇ -) upon exposure to various indicate concentrations of lipopolysaccharide (LPS, in ng/ml).
  • IL-8 interleukin 8
  • Figure 4 is a schematic depicting the extension strategy used to generate the random peptide inserts for construction of cyclic 10-mer and 7-mer random peptide phage display libraries.
  • NNK represents nucleotides that comprise the random peptide, where N is A/T/G/C and K is G/T.
  • Bold lowercase letters denote restriction enzyme sites, and "xxxxxxx” depicts additional nucleotides within the oligonucleotides.
  • Figure discloses SEQ ID NO: 98.
  • Figure 5 is a schematic depicting the method of screening of phage display libraries to identify a phage population enriched for specific binding to a TLR, and to identify polypeptide TLR ligands. Screening methods are also described in
  • Figure 6 is a graph depicting the phage titer of retained, cell-bound phage (Recovered Phage Titer, in units of 10 4 phage/ml) for each round of positive screening ("Rounds of Biopanning").
  • TLR4+/S-Tag S-Tag phage portion on
  • TLR4 expressing cells TLR4 expressing cells.
  • TLR4+/10mer 10-mer phage display library phage portion on TLR4 expressing cells.
  • TLR4-/S-Tag S-Tag phage portion on cells not expressing TLR4.
  • TLR4-/10mer 10-mer phage display library phage portion on cells not expressing TLR4.
  • Figure 7 depicts a schematic of exemplary plasmid vector T7.LIST.
  • T7.LIST is designed to express a recombinant LLO-p60 fusion protein (SEQ ID NO:
  • T7 T7 promoter.
  • Rbs ribosome binding site.
  • Figure 8 depicts activity of synthetic peptides on HEK293:TLR4 cells.
  • FIG. 10 depicts TLR4 bioactivity of new synthetic peptides identified by phage display.
  • A The response of TLR4+ HEK cells to the novel six peptides in Formulation 121a as well as to D2 in Formulation 121a and Formulation 121a alone was measured by IL-8 production.
  • B LPS is shown to have similar activity on TLR4+ HEK cells when resuspended in either PBS or Formulation 121a.
  • FIG 11 depicts activation of BMDC by synthetic peptides.
  • C3H/HeJ left and C3H/HeN (right) BMDC were cultured with the indicated peptides or known TLR ligands for 18 hours.
  • the concentrations of TNF, MCP-I, and IL-6 in the cell supernatants were determined by CBA (BDBiosciences). Values have been normalized with an unstimulated or "blank" control culture.
  • Figure 12 illustrates D2 Activation of Human DCs.
  • DCs differentiated from CD 14+ monocytes were cultured with either D2 at 10 or 50 ⁇ M, F3 at 10 or 50 ⁇ M, LPS at 10 ng/mL or 100 ng/mL. Supernatant samples were collected at 24 and 48 hours after stimulation and cytokines were detected by CBA.
  • the present invention provides novel polypeptide ligands for Toll-like Receptor 4 (TLR4).
  • TLR4 ligands modulate TLR4 signaling and thereby regulate the Innate Immune Response.
  • the polypeptide TLR4 ligands of the invention will find utility in a variety of applications.
  • the invention provides methods of modulating (e.g., antagonizing or agonizing) TLR4 signaling and the innate immune response using the polypeptide TLR4 ligands of the invention.
  • the invention also provides novel polypeptide TLR4 ligand:antigen vaccines comprising the novel polypeptide TLR4 ligands.
  • the TLR4 ligand:antigen vaccines of the invention specifically target appropriate costimulatory and regulatory elements of antigen processing and presentation and induce both cellular and humoral immunity. Furthermore, these TLR4 ligand:antigen vaccines are able to mimic the natural adjuvant-like properties of pathogenic organisms. In addition, they are amenable to industrial scale and thus would be beneficial for the prevention of infectious diseases in developing countries or against bioterrorism.
  • TLR refers to any of a family of pattern recognition receptor (PRR) proteins that are homologous to the Drosophila melanogaster Toll protein.
  • PRR pattern recognition receptor
  • TLRs are type I transmembrane signaling receptor proteins that are characterized by an extracellular leucine-rich repeat domain and an intracellular domain homologous to that of the interleukin 1 receptor.
  • the TLR family includes, but is not limited to, mammalian TLRs 1 through 11 and 13, including mouse and human TLRs 1-11 and 13.
  • TLR4 the first human TLR identified, is involved in the recognition of, for example, products of Gram-negative bacteria, such as lipopolysaccharide (LPS), products of Gram-positive bacteria such as lipoteichoic acid, the F protein of Respiratory Syncytial Vims (RSV F protein), and the envelope protein of Mouse Mammary Tumor Virus (MMTV env protein).
  • LPS lipopolysaccharide
  • RSV F protein F protein of Respiratory Syncytial Vims
  • MMTV env protein Mouse Mammary Tumor Virus
  • TLR4 interacts with MD2 and CD 14, a protein that exists both in soluble form and as a GPI-anchored protein, to induce NF- ⁇ B in response to LPS stimulation.
  • TLR4 is known to homodimerize in a multisubunit cell surface protein complex containing two monomers of TLR4, a MD2 monomer, and a CD 14 monomer.
  • TLR4 signaling is mediated through the adapter protein MyD88 but also through a MyD88-independent pathway that involved the TIR domain containing adapter protein (TIRAP).
  • TLR4 The nucleotide and amino acid sequences for TLR4 have been reported for a variety of species, including, mouse, human, chimpanzee, baboon, Rhesus monkey, dog, cat, pig, cow, rabbit, rat, chicken, and zebrafish.
  • TLR4 is a mammalian TLR4.
  • TLR4 is a mouse TLR4 (mTLR4) or a human TLR4 (hTLR4).
  • Exemplary nucleotide and amino acids sequences for mouse TLR4 are set forth in SEQ ID NOs 86 and 87, respectively. At least four different protein isoforms of TLR4 (isoforms A, B, C 5 and D) have been identified in humans. These protein isoforms, which vary in their N- terminal sequence, are the result of alternative splicing of transcripts produced from a single human TLR4 gene. Exemplary nucleotide and amino acid sequences for human TLR4 isoform A are set forth in SEQ ID NOs 88 and 89, respectively. Exemplary nucleotide and amino acid sequences for human TLR4 isoform B are set forth in SEQ ID NOs 90 and 91, respectively.
  • Exemplary nucleotide and amino acid sequences for human TLR4 isoform C are set forth in SEQ ID NOs 92 and 93, respectively.
  • Exemplary nucleotide and amino acid sequences for human TLR4 isoform D are set forth in SEQ ID NOs 94 and 95, respectively.
  • An amino acid sequence alignment of the amino acid sequences for human TLR4 isoforms A, B, C, and D is shown in Figure 2.
  • the invention provides novel polypeptide ligands for Toll-like Receptor 4 (TLR4), which modulate TLR4 signaling and thereby regulate the Innate Immune Response.
  • TLR4 Toll-like Receptor 4
  • polypeptide ligand for TLR4" and polypeptide TLR4 ligand are used interchangeably herein.
  • polypeptide or “protein” refers to a polymer of amino acid monomers that are alpha amino acids joined together through amide bonds.
  • polypeptide and protein are used interchangeably herein. Polypeptides are therefore at least two amino acid residues in length, and are usually longer.
  • peptide refers to a polypeptide that is only a few amino acid residues in length, e.g. from three to 50 amino acid residues.
  • a polypeptide in contrast with a peptide, may comprise any number of amino acid residues.
  • polypeptide includes peptides as well as longer sequences of amino acids.
  • the polypeptide TLR4 ligands of the invention comprise at least one amino acid sequence, wherein the amino acid sequence is selected from the peptide sequences set forth in Table 1.
  • a TLR4 ligand of the invention contains at least one aromatic amino acid residue (Phe, Tyr or Trp).
  • the TLR4 ligands of the invention may comprise particular motifs.
  • the motif RIG may be found in TLR4 ligands of the invention.
  • the motif IGV, and conservative variants of this motif may be present in TLR4 ligands of the invention,
  • the present invention also provides TLR4 ligands that are fragments of the above-mentioned ligands, and TLR4 ligands that are at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more homologous to the above- mentioned peptides, as well as derivates thereof, that bind to TLR4.
  • polypeptide TLR4 ligands of the invention comprise at least one of the amino acid sequences set forth in Table 1 within the context of a longer polypeptide.
  • the polypeptide TLR4 ligands of the invention may comprise a peptide sequence as set forth in Table 1 and additional polypeptide sequences attached to the N-terminus, the C-terminus, or both the N- and
  • the additional polypeptide sequences are preferably heterologous to the peptide sequence, i.e., they are not sequences which are endogenously associated with the given peptide sequence.
  • endogenously associated is meant that the given peptide sequence and the additional polypeptide sequence may be found contiguously linked in C- to N- terminal amino acid sequence orientation within a naturally occurring protein.
  • polypeptide TLR2 ligand comprises at least one of the peptide sequences set forth in Table 1 and additional polypeptide sequences, where the additional polypeptide sequences are sequences that are endogenously associated with said peptide sequence, are also contemplated.
  • polypeptide TLR4 ligands of the invention may comprise a peptide sequence as set forth in Table 1 with at least one cysteine residue attached to the N-terminus,, to the C-terminus, or to the N-terminus and to the C-terminus of the peptide sequence.
  • polypeptide TLR4 ligands of the invention comprise a peptide sequence as set forth in Table 1 with at least one cysteine residue attached to the N-terminus of the peptide sequence and at least one cysteine residue attached to the C-terminus of the peptide sequence.
  • two or more amino acid residues may be coupled to either or both ends of the polypeptide TLR4 ligands described above.
  • the sequence GG may be appended to either terminus or both termini of a polypeptide TLR4 ligand.
  • Polypeptide TLR4 ligands comprising sequence variants of the polypeptide sequences set forth in Table 1 are also contemplated. Such sequence variants include conservative variants of the polypeptide TLR4 ligands in which amino acids have been substituted for one another within one of the following groups: small aliphatic, nonpolar or slightly polar residues (Ala, Ser, Thr, Pro and GIy); polar, negatively charged residues and their amides (Asp, Asn, GIu and GIn); polar, positively charged residues (His, Arg and Lys); large aliphatic, nonpolar residues (Met, Leu, He, VaI and Cys); and aromatic residues (Phe, Tyr and Trp).
  • small aliphatic, nonpolar or slightly polar residues Al, Ser, Thr, Pro and GIy
  • polar, negatively charged residues and their amides Asp, Asn, GIu and GIn
  • His, Arg and Lys polar, positively charged residues
  • substitutions selected may be based, for example, on analyses of structure-forming potentials (Chou et al Biochemistry 1974; 13:211 and Schulz et al. Principles in Protein Structure. Springer Verlag. 1978:pp. 108-130), and on the analysis of hydrophobicity patterns in proteins (Kyte et al. J. MoI, Biol. 1982;157:105-132).
  • sequence variants may also include polypeptide TLR4 ligands with altered overall charge, structure, hydrophobicity/hydrophilicity properties produced by amino acid substitution, insertion, or deletion that retain and/or improve the ability to modulate TLR4 signaling.
  • Stereoisomers e.g., D-amino acids
  • conventional amino acids unnatural amino acids such as a,a-disubstituted amino acids, N-alkyl amino acids, lactic acid, and other unconventional amino acids may also be suitable components for polypeptide TLR4 ligands of the present invention.
  • unconventional amino acids include, but are not limited to: ⁇ -alanine, 3- pyridylalanine, 4-hydroxyproline, O-phosphoserine, N-methylglycine (also known as sarcosine), N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, nor-leucine, 1-naphthylalanine (1-nal), 2-naphthylalanine (2-nal), homoserine methylether (Hsm), N-acetylglycine, and other similar amino acids and imino acids.
  • modifications are also possible, including modification of the amino terminus, modification of the carboxy terminus, replacement of one or more of the naturally occurring genetically encoded amino acids with an unconventional amino acid, modification of the side chain of one or more amino acid residues, peptide phosphorylation, and the like.
  • the amino terminus of the peptide may be modified by acetylation (e.g., with acetic acid or a halogen substituted acetic acid). See also the section "Preparation of the polypeptide TLR4 ligands of the invention: Polypeptide modifications", below.
  • polypeptide TLR4 ligands of the invention may be prepared by any of the techniques well known in the art, including translation from coding sequences and in vitro chemical synthesis.
  • the polypeptide TLR4 ligands of the invention may be prepared by translation of a nucleic acid sequence encoding the polypeptide TLR4 ligand.
  • nucleic acids may be obtained by any of the synthetic or recombinant DNA methods well known in the art. See, for example, Glover, DNA Cloning: A Practical Approach. 2 nd Edition. Volumes I-IV. (Oxford University Press, 1999); Oligonucleotide Synthesis (Gait ed.:1984); Transcription And Translation (Hames & Higgins, eds.:1984); Perbal. A Practical Guide To Molecular Cloning (1984); Ausubel et ah, eds.
  • nucleic acids encoding a polypeptide TLR4 ligand can easily be synthesized by chemical techniques, for example, the phosphotriester method (Matteucci et al. J. Am. Chem. Soc. 1981 ; 103 :3185-3191 ) or using automated synthesis methods.
  • Translation of the polypeptide TLR4 ligands of the invention may be achieved in vitro (e.g. via in vitro translation of a linear nucleic acid encoding the polypeptide TLR4 ligand) or in vivo (e.g. by recombinant expression of an expression construct encoding the polypeptide TLR4 ligand).
  • Techniques for in vitro and in vivo expression of peptides from a coding sequence are well known in the art. See, for example, Glover, DNA Cloning: A Practical Approach. 2 nd Edition. Volumes I-IV.
  • the polypeptide TLR4 ligands of the invention are prepared by in vitro translation of a nucleic acid encoding the polypeptide TLR4 ligand.
  • a number of cell-free translation systems have been developed for the translation of isolated mRNA, including rabbit reticulocyte lysate, wheat germ extract, and E. coli S30 extract systems (Jackson and Hunt. Meth Enz 1983;96:50-74; Ambion Technical Bulletin #187; and Hurst. Promega Notes 1996;58:8). Kits for in vitro transcription and translation are available from a wide variety of commercial sources including Promega, Ambion, Roche Applied Science, Novagen, Invitrogen, PanVera, and Qiagen.
  • kits for in vitro translation using reticulocyte or wheat germ lysates are commercially available from Ambion.
  • reticulocyte lysate is programmed with the PCR DNA using TNT T7 Quick for PCR DNA kit (Promega), which couples transcription to translation.
  • TNT T7 Quick for PCR DNA kit Promega
  • the DNA template is incubated at 3O 0 C for 60-90 min in the presence of rabbit reticulocyte lysate, RNA polymerase, amino acid mixture and RNAsin ribonuclease inhibitor.
  • polypeptide TLR4 ligands are translated from an expression construct, wherein a nucleic acid encoding the polypeptide TLR4 ligand is operatively associated with expression control sequence elements which provide for the proper transcription and translation of the polypeptide TLR4 ligand within the chosen host cells.
  • sequence elements may include a promoter, a polyadenylation signal, and optionally internal ribosome entry sites (IRES) and other ribosome binding site sequences, enhancers, response elements, suppressors, signal sequences, and the like. Codon selection, where the target nucleic acid sequence of the construct is engineered or chosen so as to contain codons preferentially used within the desired host call, may be used to minimize premature translation termination and thereby maximize expression.
  • the nucleic acid sequence may also encode a peptide tag for easy identification and purification of the translated polypeptide TLR4 ligand.
  • Peptide tags include, but are not limited too, GST 5 myc, His, and FLAG tags.
  • the encoded peptide tag may include recognition sites for site-specific proteolysis or chemical agent cleavage to facilitate removal of the peptide tag following protein purification. For example a thrombin cleavage site could be incorporated between a polypeptide TLR4 ligand and its peptide tag.
  • the promoter sequences may be endogenous or heterologous to the host cell to be modified, and may provide ubiquitous (i.e., expression occurs in the absence of an apparent external stimulus) or inducible (i.e., expression only occurs in presence of particular stimuli) expression.
  • Promoters which may be used to control gene expression include, but are not limited to: the cytomegalovirus (CMV) promoter (U.S. Patents No. 5,385,839 and No. 5,168,062); the SV40 early promoter region (Benoist and Chambon. Nature 1981 ;290:304-310); the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al.
  • herpes thymidine kinase promoter (Wagner et al Proc. Natl Acad. ScL USA 1981 ;78: 1441 -1445); the regulatory sequences of the metallothionein gene (Brinster et al Nature 1982;296:39-42); prokaryotic promoters such as the alkaline phosphatase promoter, the trp-lac promoter, the bacteriophage lambda PL promoter, the T7 promoter, the beta-lactamase promoter (Villa-Komaroff et al Proc. Natl Acad.
  • the expression constructs may further comprise vector sequences that facilitate the cloning and propagation of the expression constructs.
  • vectors including plasmid and fungal vectors, have been described for replication and/or expression in a variety of eukaryotic and prokaryotic host cells.
  • Standard vectors useful in the current invention are well known in the art and include (but are not limited to) plasmids, cosmids, phage vectors, viral vectors, and yeast artificial chromosomes.
  • the vector sequences may contain, for example, a replication origin for propagation in E.
  • a plasmid is a common type of vector.
  • a plasmid is generally a self-contained molecule of double-stranded DNA, usually of bacterial origin, that can readily accept additional foreign DNA and that can readily be introduced into a suitable host cell.
  • a plasmid vector generally has one or more unique restriction sites suitable for inserting foreign DNA.
  • plasmids that may be used for expression in prokaryotic cells include, but are not limited to, pBR322-derived plasmids, pEMBL-derived plasmids, pEX-derived plasmids, pBTac-derived plasmids, pUC-derived plasmids, and pET-LIC-derived plasmids.
  • nucleic acids to host cells are well established in the art, including, but not limited to, electroporation, microinjection, liposome-mediated transfection, calcium phosphate-mediated transfection, or virus- mediated transfection. See, for example, Artificial self-assembling systems for gene delivery. Feigner et al, eds. (Oxford University Press: 1996); Lebkowski et al MoI Cell Biol 1988;8:3988-3996; Sambrook et al. Molecular Cloning: A Laboratory Manual 2 nd Edition (Cold Spring Harbor Laboratory: 1989); and Ausubel et al, eds. Current Protocols in Molecular Biology (John Wiley & Sons: 1989).
  • An expression construct encoding a polypeptide TLR.4 ligand may be transfected into host cells in vitro.
  • host cells include various strains of E. coli., yeast, Drosophila cells (e.g. S-2 cells), and mammalian cells.
  • Preferred in vitro host cells are mammalian cell lines including BHK-21, MDCK, Hu609, MAC-T (U.S. Patent No. 5,227,301), Rl embryonic stem cells, embryonal carcinoma cells, COS, HEK293 cells (ATCC Accession # CRL-1573), and HeLa cells. Protocols for in vitro culture of mammalian cells are well established in the art. See, for example, Animal Cell Culture: A Practical Approach 3 rd Edition. J. Masters, ed. (Oxford University Press) and Basic Cell Culture 2 nd Edition. Davis, ed. (Oxford University Press:2002).
  • polypeptide TLR4 ligands of the invention may be prepared via in vitro chemical synthesis by classical methods known in the art. These standard methods include exclusive solid phase synthesis, partial solid phase synthesis methods, fragment condensation, and classical solution synthesis. See, e.g., Merrifield. J. Am. Chem. Soc. 1963;85:2149.
  • a preferred method for polypeptide synthesis is solid phase synthesis.
  • Solid phase polypeptide synthesis procedures are well-known in the art. See, e.g., Stewart Solid Phase Peptide Syntheses (Freeman and Co.: San Francisco: 1969); 2002/2003 General Catalog from Novabiochem Corp, San Diego, USA; and Goodman Synthesis of Peptides and Peptidomimetics (Houben-Weyl, Stuttgart:2002).
  • synthesis is typically commenced from the C-terminal end of the polypeptide using an ⁇ -amino protected resin.
  • a suitable starting material can be prepared, for instance, by attaching the required ⁇ -amino acid to a chloromethylated resin, a hydroxymethyl resin, a polystyrene resin, a benzhydrylamine resin, or the like.
  • a chloromethylated resin is sold under the trade name BIO-BEADS SX- 1 by Bio Rad Laboratories (Richmond, CA).
  • BIO-BEADS SX- 1 Bio Rad Laboratories (Richmond, CA).
  • BIO-BEADS SX- 1 Bio Rad Laboratories (Richmond, CA).
  • BIO-BEADS SX- 1 Bio Rad Laboratories (Richmond, CA).
  • BIO-BEADS SX- 1 Bio Rad Laboratories (Richmond, CA).
  • the preparation of the hydroxymethyl resin has been described (Bodonszky et al. Chem. Ind. London 1966;38:1597).
  • the benzhydrylamine (BHA) resin has been described (Pietta and Marshall
  • an ⁇ -amino protected amino acid may be coupled to a chloromethylated resin with the aid of a cesium bicarbonate catalyst (Gisin. HeIv. CUm. Acta 1973 ;56: 1467).
  • the ⁇ -amino protecting group is removed, for example, using trifluoroacetic acid (TFA) or hydrochloric acid (HCl) solutions in organic solvents at room temperature. Thereafter, ⁇ -amino protected amino acids are successively coupled to a growing support-bound polypeptide chain.
  • TFA trifluoroacetic acid
  • HCl hydrochloric acid
  • the ⁇ -amino protecting groups are those known to be useful in the art of stepwise synthesis of polypeptides, including: acyl-type protecting groups (e.g., formyl, trifluoroacetyl, acetyl), aromatic urethane-type protecting groups [e.g., benzyloxycarboyl (Cbz) and substituted Cbz], aliphatic urethane protecting groups [e.g., t-butyloxycarbonyl (Boc), isopropyloxycarbonyl, cyclohexyloxycarbonyl], and alkyl type protecting groups (e.g., benzyl, triphenylmethyl), fluorenylmethyl oxycarbonyl (Fmoc), allyloxycarbonyl (Alloc), and l-(4,4-dimethyl-2,6-dioxocyclohex-l-ylidene)ethyl (Dde).
  • acyl-type protecting groups
  • the side chain protecting groups (typically ethers, esters, trityl, PMC, and the like) remain intact during coupling and are not split off during the deprotection of the amino-terminus protecting group or during coupling.
  • the side chain protecting group must be removable upon the completion of the synthesis of the final polypeptide and under reaction conditions that will not alter the target polypeptide.
  • the side chain protecting groups for Tyr include tetrahydropyranyl, tert- butyl, trityl, benzyl, Cbz, Z-Br-Cbz, and 2,5-dichlorobenzyl.
  • the side chain protecting groups for Asp include benzyl, 2,6-dichlorobenzyl, methyl, ethyl, and cyclohexyl.
  • the side chain protecting groups for Thr and Ser include acetyl, benzoyl, trityl, tetrahydropyranyl, benzyl, 2,6-dichlorobenzyl, and Cbz.
  • the side chain protecting groups for Arg include nitro, Tosyl (Tos), Cbz, adamantyloxycarbonyl mesitoylsulfonyl (Mts), 2,2,4,6,7-pentamethyldihydrobenzofurane-5-sulfonyl (Pbf), 4- mthoxy-2,3,6-trimethyl-benzenesulfonyl (Mtr), or Boc.
  • the side chain protecting groups for Lys include Cbz, 2-chlorobenzyloxycarbonyl (2-Cl-Cbz), 2- bromobenzyloxycarbonyl (2-Br-CbZ), Tos, or Boc.
  • each protected amino acid is generally reacted in about a 3 -fold excess using an appropriate carboxyl group activator such as 2-(lH-benzotriazol-l-yl)-l,l,3,3 tetramethyluronium hexafluorophosphate (HBTU) or dicyclohexylcarbodimide (DCC) in solution, for example, in methylene chloride (CH 2 Cl 2 ), N-methyl pyrrolidone, dimethyl formamide (DMF), or mixtures thereof.
  • carboxyl group activator such as 2-(lH-benzotriazol-l-yl)-l,l,3,3 tetramethyluronium hexafluorophosphate (HBTU) or dicyclohexylcarbodimide (DCC) in solution, for example, in methylene chloride (CH 2 Cl 2 ), N-methyl pyrrolidone, dimethyl formamide (DMF), or mixtures thereof.
  • the desired polypeptide is decoupled from the resin support by treatment with a reagent, such as trifluoroacetic acid (TFA) or hydrogen fluoride (HF), which not only cleaves the polypeptide from the resin, but also cleaves all remaining side chain protecting groups.
  • a reagent such as trifluoroacetic acid (TFA) or hydrogen fluoride (HF)
  • TFA trifluoroacetic acid
  • HF hydrogen fluoride
  • the side chain protected polypeptide can be decoupled by treatment of the polypeptide resin with ammonia to give the desired side chain protected amide or with an alkylamine to give a side chain protected alkylamide or dialkylamide. Side chain protection is then removed in the usual fashion by treatment with hydrogen fluoride to give the free amides, alkylamides, or dialkylamides.
  • the resins used to prepare the peptide acids are employed, and the side chain protected polypeptide is cleaved with base and the appropriate alcohol (e.g., methanol). Side chain protecting groups are then removed in the usual fashion by treatment with hydrogen fluoride to obtain the desired ester.
  • Synthetic amino acids that can be substituted into the polypeptides of the present invention include, but are not limited to, N -methyl, L-hydroxypropyl, L ⁇ 3, 4- dihydroxyphenylalanyl, ⁇ amino acids such as L- ⁇ -hydroxylysyl and D- ⁇ - methylalanyl, L- ⁇ -methylalanyl, ⁇ amino acids, and isoquinolyl.
  • D-amino acids and non-naturally occurring synthetic amino acids can also be incorporated into the polypeptides of the present invention.
  • Amino terminus modifications include methylation (e.g., -NHCH 3 or -N(CH 3 )2), acetylation (e.g., with acetic acid or a halogenated derivative thereof such as ⁇ -chloroacetic acid, ⁇ -bromoacetic acid, or ⁇ - iodoacetic acid), adding a benzyloxycarbonyl (Cbz) group, or blocking the amino terminus with any blocking group containing a carboxylate functionality defined by RCOO- or sulfonyl functionality defined by R-SO 2 -, where R is selected from alkyl, aryl, heteroaryl, alkyl aryl, and the like, and similar groups.
  • the N-terminus may be acetylated to yield N- acetylglycine.
  • Carboxy terminus modifications include replacing the free acid with a carboxamide group or forming a cyclic lactam at the carboxy terminus to introduce structural constraints.
  • C-terminal functional groups of the compounds of the present invention include amide, amide lower alkyl, amide di(lower alkyl), lower alkoxy, hydroxy, and carboxy, and the lower ester derivatives thereof, and the pharmaceutically acceptable salts thereof.
  • proline analogues in which the ring size of the proline residue is changed from 5 members to 4, 6, or 7 members can be employed. Cyclic groups can be saturated or unsaturated, and if unsaturated, can be aromatic or non-aromatic.
  • Heterocyclic groups preferably contain one or more nitrogen, oxygen, and/or sulfur heteroatoms.
  • groups include the furazanyl, furyl, imidazolidinyl, imidazolyl, imidazolinyl, isothiazolyl, isoxazolyl, morpholinyl (e.g.
  • morpholino oxazolyl, piperazinyl (e.g., 1 -piperazinyl), piperidyl (e.g., l ⁇ piperidyl, piperidino), pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolidinyl (e.g., 1 -pyrrolidinyl), pyrrolinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, thiomorpholinyl (e.g., thiomorpholino), and triazolyl.
  • These heterocyclic groups can be substituted or unsubstituted. Where a group is substituted, the substituent can be alkyl, alkoxy, halogen, oxygen, or substituted or unsubstituted phenyl.
  • polypeptides can also readily modify polypeptides by phosphorylation, and other methods (e.g. , as described in Hruby et al. Biochem J. 1990;268:249-262).
  • the invention also contemplates partially or wholly non-peptidic analogs of the polypeptide TLR4 ligands of the invention.
  • the peptide compounds of the invention also serve as structural models for non-peptidic compounds with similar biological activity.
  • Those of skill in the art recognize that a variety of techniques are available for constructing compounds with the same or similar desired biological activity as the lead peptide compound, but with more favorable activity than the lead with respect to solubility, stability, and susceptibility to hydrolysis and proteolysis. See, e.g., Morgan and Gainor. Ann. Rep. Med Chem. 1989;24 -.243-252. These techniques include replacing the polypeptide backbone with a backbone composed of phosphonates, amidates, carbamates, sulfonamides, secondary amines, or N-methylaniino acids.
  • the contemplated analogs of polypeptide TLR4 ligands are polypeptide-containing molecules that mimic elements of protein secondary structure. See, for example, Johnson et al. "Peptide Turn Mimetics," in Biotechnology and Pharmacy. Pezzuto et al., eds. (Chapman and Hall: 1993). Such molecules are expected to permit molecular interactions similar to the natural molecule.
  • analogs of polypeptides are commonly used in the pharmaceutical industry as non-polypeptide drugs with properties analogous to those of a subject polypeptide (Fauchere Adv. Drug Res. 1986; 15:29-69; Veber et al. Trends Neurosci. 1985;8:392-396; and Evans et al.
  • Fully synthetic analogs of the polypeptide TLR4 ligands of the invention can be constructed by structure-based drug design through replacement of amino acids by organic moieties. See, for example, Hughes Philos. Trans. R. Soc. Lond. 1980;290:387-394; Hodgson Biotechnol 1991;9:19-21 and Suckling. Sci. Prog. 1991;75:323-359.
  • the polypeptide TLR4 ligands of the invention modulate TLR4 signaling
  • the polypeptide TLR4 ligands of the invention are preferably functional TLR4 ligands, i. e. they modulate TLR4 signaling.
  • TLR4 signaling refers to any intracellular signaling pathway initiated by activated
  • TLR4 including shared pathways (e.g., activation of NF- ⁇ B) and TLR4-specific pathways.
  • modulating TLR4 signaling includes both activating ⁇ i.e. agonizing) TLR4 signaling and suppressing (i.e. antagonizing) TLR4 signaling.
  • a polypeptide TLR4 ligand that modulates TLR4 signaling may be a TLR4 agonist or a TLR4 antagonist.
  • a TLR4 antagonist binds TLR4 but does not activate TLR4+ cells.
  • polypeptides of the invention may be assessed using a variety of assay systems well known in the art.
  • the ability of a polypeptide of the invention to modulate TLR4 signaling is measured in a dendritic cell (DC) activation assay.
  • DC dendritic cell
  • Murine DCs may be generated in vitro as previously described (Lutz et a J Immun Meth. 1999;223:77- 92).
  • bone marrow cells from 6-8 week old C57BL/6 mice are isolated and cultured for 6 days in medium supplemented with 100 U/ml GMCSF, replenishing half the medium every two days. On day 6, nonadherent cells are harvested and resuspended in medium without GMSCF and used in the DC activation assay.
  • Human DCs may be obtained commercially (Cambrex, Walkersville, MD) or generated in vitro from peripheral blood obtained from healthy donors as previously described (Sallusto & Lanzavecchla. J Exp Med 1994;179:1109-1118).
  • peripheral blood mononuclear cells PBMC
  • Cells from the 42.5-50% interface are harvested and further purified following magnetic bead depletion of B- and T-cells using antibodies to CD 19 and CD2, respectively.
  • the resulting DC enriched suspension is cultured for 6 days in medium supplemented with 100 U/ml GMCSF and 1000 U/ml IL-4.
  • nonadherant cells are harvested and resuspended in medium without cytokines and used in the DC activation assay.
  • a polypeptide TLR4 ligand is added to DC cells in culture and the cultures are incubated for 16 hours.
  • Supernatants are harvested, and cytokine ⁇ e.g., IFN ⁇ , TNFoc, IL- 12, IL-10 and/or IL- 6) concentrations are determined, e.g., by sandwich enzyme-linked immunosorbent assay (ELISA) using matched antibody pairs from BD Pharmingen or R&D Systems, following the manufacturer's instructions.
  • ELISA sandwich enzyme-linked immunosorbent assay
  • Cells are harvested, and costimulatory molecule expression ⁇ e.g., B7-22) is determined by flow cytometry using antibodies from BD Pharmingen or Southern Biotechnology Associates following the manufacturer's instructions; analysis is performed on a Becton Dickinson FACScan running Cellquest software.
  • Functional polypeptide TLR4 ligands stimulate cytokine and/or co-stimulatory molecule expression in the DC assay.
  • the ability of a polypeptide of the invention to modulate expression of an NF- ⁇ B-reporter gene in a TLR4-dependent manner is assessed.
  • one of the shared pathways of TLR signaling results in the activation of the transcription factor NF- ⁇ B. Therefore, expression of an NF -KB- dependent reporter gene can serve as an indicator of active TLR signaling.
  • the ability of a polypeptide TLR4 ligand to modulate expression of an NF- ⁇ B- dependent reporter gene in a TLR4 non-expressing cell i.e. the cell expresses very little or no TLR4
  • a TLR4 non-expressing cell i.e. the cell expresses very little or no TLR4
  • a polypeptide TLR4 ligand will significantly modulate NF- ⁇ B-dependent reporter gene expression in a TLR4-expressing cell, but not in a TLR4 non-expressing cell.
  • HEK293 cells do not express detectable levels of endogenous TLR4.
  • HEK293 cells harboring an NF- ⁇ B-dependent luciferase reporter gene, and ectopically expressing human TLR4 isoform A, human TLR4 isoform A and the accessory molecules MD2 and CD 14, or mouse TLR4 are available from Invivogen (Catalogue numbers 293- htlr4A, 293-htlr4A/MD2-CD14, and 293-mtlr4, respectively).
  • HEK293-hTLR4A/MD2-CD14 cells are grown in standard Dulbecco's Modified Eagle Medium (DMEM) medium with 10% Fetal Bovine Serum (FBS) supplemented with blasticidin (lO ⁇ g/ml) and then exposed to peptide ligands. Luciferase activity is then quantitated using commercial reagents.
  • DMEM Dulbecco's Modified Eagle Medium
  • FBS Fetal Bovine Serum
  • blasticidin lO ⁇ g/ml
  • the ability of a polypeptide of the invention to induce interleukin-8 (IL-8) expression in a TLR4-dependent manner is assessed.
  • the ability of a polypeptide TLR4 ligand to induce IL-8 expression in a TLR4 non-expressing cell (/. e. the cell expresses very little or no TLR4) versus in a TLR4-expressing cell is compared.
  • a polypeptide TLR4 ligand will significantly induce IL-8 expression in a TLR4-expressing cell, but not in a TLR4 non-expressing cell.
  • HEK293 do not express detectable levels of endogenous TLR4.
  • HEK293 cells ectopically expressing human TLR4 isoform A, human TLR4 isoform A and the accessory molecules MD2 and CD 14, or mouse TLR4 are available from Invivogen (Catalogue numbers 293-htlr4A, 293-htlr4A/MD2-CD14, and 293-mtlr4, respectively).
  • HEK293-hTLR4/MD2-CD14 cells are grown in standard Dulbecco's Modified Eagle Medium (DMEM) medium with 10% Fetal Bovine Serum (FBS) supplemented with blasticidin (10 ⁇ g/ml), and then exposed to a polypeptide TLR4 ligand.
  • DMEM Dulbecco's Modified Eagle Medium
  • FBS Fetal Bovine Serum
  • IL-8 expression may then be quantitated by standard methods well known in the art, including Northern Blotting to detect IL-8 mRNA, immunostaining of a Western Blot to detect IL-8 protein, fluorescence activated cell sorter (FACS) analysis using an anti-IL-8 antibody, or sandwich enzyme linked immunosorbent assay (ELISA) using matched antibody pairs specific for IL-8.
  • FACS fluorescence activated cell sorter
  • ELISA sandwich enzyme linked immunosorbent assay
  • the TLR4 antagonist activity of a polypeptide TLR4 ligand can be assessed in variations of the above described assays, wherein the inhibitory effect of a polypeptide TLR4 ligand on TLR4 activation by a known TLR4 agonist (such as LPS) is quantitated.
  • a known TLR4 agonist such as LPS
  • a cell that comprises TLR4 is any cell that contains TLR4 protein, including cells that endogenously express TLR4; cells that do not endogenously express TLR4 but are ectopically expressing TLR4; and cells that endogenously express TLR4 and are ectopically expressing additional TLR4.
  • the cells are mammalian cells.
  • the cells are mouse cell or human cells. The cells may be cells cultured in vitro or cells in vivo.
  • Cells that endogenously express TLR4 include NIH3T3 cells (ATCC Accession # CRL- 1658), RAW264.7 cells (ATCC Accession # TIB-71), dendritic cells, macrophages, B-cells, and natural killer cells.
  • Cells that do not endogenously express TLR4 include HEK293 cells (ATCC Accession # CRL-1573), HEK293:Null cells (Invivogen Accession #293-null) and 293T/17 cells (ATCC Accession # CRL- 11268)
  • TLR4 Cells that ectopically express TLR4 may be generated by standard techniques well known in the art. For example, pUNO-mTLR4, pUNO-hTLR4, p- DUO-hCD14/hTLR4, and pDUO ⁇ hMD2/hTLR4 plasmids are available from Invivogen. These plasmids provide for high-level TLR4 expression in mammalian host cells (e.g., HEK293 and NIH3T3 cells).
  • mammalian host cells e.g., HEK293 and NIH3T3 cells.
  • the TLR4 expression status of a cell may be determined by any of the techniques well established in the art including Western blotting, immunoprecipitation, flow cytometry / FACS, immunohistochemistry/immunocytochemistry, Northern blotting, RT-PCR, whole mount in situ hybridization, etc.
  • monoclonal and polyclonal antibodies to human or mouse TLR4 are commercially available, e.g., from BioVision, Cell Sciences, IMGENEX, Novus Biologicals, R&D Systems, Serotec Inc., Stressgen Bioreagents, and Zymed.
  • Human TLR4 and mouse TLR4 primer pairs are commercially available, e.g., from Invivogen and Bioscience Coiporation.
  • a SuperArray RT-PCR Profiling Kit for simultaneous quantitation of the expression of mouse TLRs 1 through 9 or human TLRs 1 through 10 is available from Bioscience Corporation.
  • TLR4 signaling For a discussion of TLR4 signaling and assays to detect modulation of TLR4 signaling see the section The polypeptide TLR4 ligands of the invention modulate TLR4 signaling, above
  • Vaccines comprising polypeptide TLR4 ligands
  • the invention also provides vaccines comprising at least one polypeptide TLR4 ligand of the invention and at least one antigen.
  • These vaccines combine both signals required for the induction of a potent adaptive immune response: an innate immune system signal (i.e. TLR4 signaling), and an antigen receptor signal (antigen).
  • TLR4 signaling an innate immune system signal
  • antigen receptor signal antigen receptor signal
  • these vaccines may be used in methods to generate a potent antigen-specific immune response. In particular, these vaccines may used in situations where TLR4 receptor signaling is desired. It is preferred that in the vaccines of the invention the at least one polypeptide TLR4 ligand and at least one antigen are covalently linked.
  • polypeptide TLR4 ligand;antigen vaccine refers to a vaccine composition comprising at least one polypeptide TLR4 ligand of the invention and at least one antigen, wherein the polypeptide TLR4 ligand and the antigen are covalently linked. Without intending to be limited by mechanism, it is thought that covalent linkage ensures that every cell that is exposed to antigen also receives an TLR4 receptor innate immune signal and vice versa.
  • vaccines comprising at least one polypeptide TLR4 ligand and at least one antigen, in which the at least one polypeptide TLR4 ligand and the at least one antigen are mixed or associated in a non-covalent fashion, e.g. electrostatic interaction, are also contemplated.
  • composition of the vaccines of the invention comprise at least one polypeptide TLR4 ligand of the invention and at least one antigen.
  • the vaccines of the invention comprise at least one polypeptide TLR4 ligand, where the polypeptide TLR4 ligand comprises at least one peptide selected from the peptides set forth in Table 1, and at least one antigen. In some embodiments, the vaccines of the invention comprise at least one polypeptide TLR4 ligand, wherein the polypeptide TLR4 ligand comprises at least one of the peptide sequences set forth in Table 1 within the context of a longer polypeptide.
  • the vaccine may comprise at least one polypeptide TLR4 ligand, where the polypeptide TLR4 ligand comprises a peptide sequence as set forth in Table I 3 and additional polypeptide sequences attached to the N-terminus, the C-terminus, or both the N- and C- termini of the peptide sequence.
  • the additional polypeptide sequences are preferably heterologous to the peptide sequence, i.e., they are not sequences which are endogenously associated with the given peptide sequence.
  • polypeptide TLR4 ligand comprises at least one of the peptide sequences set forth in Table 1 and additional polypeptide sequences, where the additional polypeptide sequences are sequences that are endogenously associated with said peptide sequence, are also contemplated.
  • the vaccines of the invention may comprise a peptide sequence as set forth in Table 1 with at least one cysteine residue attached to the N-terminus, to the C-terminus, or to the N-terminus and to the C-terminus of the peptide sequence.
  • the vaccines of the invention comprise a peptide sequence as set forth in Table 1 with at least one cysteine residue attached to the N-terminus and at least one cysteine residue attached to the C-terminus of the peptide sequence.
  • the antigens used in the vaccines of the present invention can be any type of antigen, including but not limited to pathogen-related antigens, tumor-related antigens, allergy-related antigens, neural defect-related antigens, cardiovascular disease antigens, rheumatoid arthritis-related antigens, other disease-related antigens, hormones, pregnancy-related antigens, embryonic antigens and/or fetal antigens and the like.
  • the antigen component of the vaccine can be derived from sources that include, but are not limited to, bacteria, viruses, fungi, yeast, protozoa, metazoa, tumors, malignant cells, plants, animals, humans, allergens, hormones and amyloid ⁇ peptide.
  • the antigens may be composed of, e.g., polypeptides, lipoproteins, glycoproteins, mucoproteins, lipids, saccharides, lipopolysaccharides, nucleic acids, and the like.
  • pathogen-related antigens include, but are not limited to, antigens selected from the group consisting of West Nile Virus (WNV, e.g., envelope protein domain EIII antigen) or other Flaviviridae antigens, Listeria monocytogenes (e.g., LLO or p60 antigens), Influenza A virus (e.g., the M2e antigen), vaccinia virus, avipox virus, turkey influenza virus, bovine leukemia virus, feline leukemia virus, chicken pneumovirosis virus, canine parvovirus, equine influenza, Feline rhinotracheitis virus (FHV), Newcastle Disease Virus (NDV), infectious bronchitis virus; Dengue virus, measles virus, Rubella virus, pseudorabies, Epstein- Barr Virus, Human Immunodeficieny Virus (HIV), Simian Immunodeficiency virus (SIV), Equine Herpes Vims (EHV), Bovine Herpes Virus
  • tetani mumps, Morbillivirus, Herpes Simplex Virus type 1, Herpes Simplex Virus type 2, Human cytomegalovirus, Hepatitis A Virus, Hepatitis B Virus, Hepatitis C Virus, Hepatitis E Virus, Respiratory Syncytial Virus, Human Papilloma Virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium, Toxoplasma, Cryptococcus, Streptococcus, Staphylococcus, Haemophilus, Diptheria, Pertussis, Escherichia, Candida, Aspergillus, Entamoeba, Giardia, and Trypanosoma.
  • the methods and compositions of the present invention can also be used to produce vaccines directed against tumor-associated antigens such as melanoma-associated antigens, mammary cancer-associated antigens, colorectal cancer-associated antigens, prostate cancer-associated antigens and the like.
  • tumor-associated antigens such as melanoma-associated antigens, mammary cancer-associated antigens, colorectal cancer-associated antigens, prostate cancer-associated antigens and the like.
  • tumor-related or tissue-specific antigens useful in such vaccines include, but are not limited to, antigens selected from the group consisting of prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), Her-2, epidermal growth factor receptor, gpl20, p24, and FRAME.
  • PSA prostate-specific antigen
  • PSMA prostate-specific membrane antigen
  • Her-2 epidermal growth factor receptor
  • gpl20, p24 FRAME
  • the methods and compositions of the present invention can also be used to produce vaccines directed against tumor vascularization.
  • target antigens for such vaccines are vascular endothelial growth factors, vascular endothelial growth factor receptors, fibroblast growth factors and fibroblast growth factor receptors and the like.
  • Specific examples of allergy-related antigens useful in the methods and compositions of the present invention include, but are not limited to: allergens derived from pollen, such as those derived from trees such as Japanese cedar (Cryptomeria, Cryptomeriajaponic ⁇ ), grasses (Gramineae), such as orchard-grass (e.g. Dactylis glomerat ⁇ ), weeds such as ragweed (e.g.
  • Ambrosia artemisiifoli ⁇ specific examples of pollen allergens including the Japanese cedar pollen allergens Cry j 1 and Ciy j 2, and the ragweed allergens Amb a Ll 3 Amb a 1.2, Amb a 1.3, Amb a 1.4, Amb a II etc.; allergens derived from fungi (e.g. Aspergillus, Candida, Alternaria, etc.); allergens derived from mites (e.g.
  • vaccines directed against antigens that are associated with diseases other than cancer, allergy and asthma.
  • an extracellular accumulation of a protein cleavage product of ⁇ -amyloid precursor protein, called "amyloid- ⁇ peptide” is associated with the pathogenesis of Alzheimer's disease.
  • the vaccines of the present invention can comprise an amyloid- ⁇ polypeptide.
  • the vaccines of the invention may additionally comprise earner molecules such as polypeptides (e.g., keyhole limpet hemocyanin (KLH)), liposomes, insoluble salts of aluminum (e.g. aluminum phosphate or aluminum hydroxide), polynucleotides, polyelectrolytes, and water soluble earners (e.g. muramyl dipeptides).
  • a polypeptide TLR4 ligand and/or antigen can, for example, be covalently linked to a carrier molecule using standard methods. See, for example, Hancock et al. "Synthesis of Peptides for Use as Immunogens," in Methods in Molecular Biology: Immunochemical Protocols, Manson (ed.), pages 23-32 (Humana Press: 1992).
  • the vaccines of the invention comprise at least one polypeptide TLR4 ligand of the invention chemically conjugated to at least one antigen.
  • Methods for the chemical conjugation of polypeptides, carbohydrates, and/and lipids are well known in the art. See, for example, Hermanson. Bioconjugate
  • Heterobifunctional crosslinkers such as sulfosuccinimidyl (4- iodoacetyl) aminobenzoate, which link the epsilon amino group on the D-lysine residues of copolymers of D-lysine and D-glutamate to a sulfhydryl side chain from an amino terminal cysteine residue on the peptide to be coupled, may be used to increase the ratio of polypeptide TLR4 ligand to antigen in the conjugate.
  • Polypeptide TLR4 ligands and polypeptide antigens will contain amino acid side chains such as amino, carbonyl, hydroxyl, or sulfhydryl groups or aromatic rings that can serve as sites for linking the polypeptide TLR4 ligands and polypeptide antigens to each other, or for linking the polypeptide TLR4 ligands to an non- polypeptide antigen. Residues that have such functional groups may be added to either the polypeptide TLR4 ligands or polypeptide antigens. Such residues may be incorporated by solid phase synthesis techniques or recombinant techniques, both of which are well known in the art.
  • Polypeptide TLR4 ligands and polypeptide antigens may be chemically conjugated using conventional crosslinking agents such as carbodiimides.
  • carbodiimides are l-cyclohexyl-3-(2 ⁇ morpholinyl-(4-ethyl) carbodiimide (CMC), l-ethyl-3-(3-dimethyaminopropyl) carbodiimide (EDC), and l-ethyl-3-(4-azonia-44-dimethyl ⁇ entyl) carbodiimide.
  • any of a number of homobifunctional agents including a homobifunctional aldehyde, a homobifunctional epoxide, a homobifunctional imidoester, a homobifunctional N-hydroxysuccinimide ester, a homobifunctional maleimide, a homobifunctional alkyl halide, a homobifunctional pyridyl disulfide, a homobifunctional aryl halide, a homobifunctional hydrazide, a homobifunctional diazonium derivative and a homobifunctional photoreactive compound may be used.
  • heterobifunctional compounds for example, compounds having an amine-reactive and a sulfhydryl -reactive group, compounds with an amine-reactive and a photoreactive group and compounds with a carbonyl-reactive and a sulfhydryl-reactive group.
  • homobifunctional crosslinking agents include the bifunctional N-hydroxysuccinimide esters dithiobis (succinimidylpropionate), disuccinimidyl suberate, and disuccinimidyl tartarate; the bifunctional imidoesters dimethyl adipimidate, dimethyl pimelimidate, and dimethyl suberimidate; the bifunctional sulfhydryl-reactive crosslinkers l,4-di-[3'-(2'-pyridyldithio) propion-amido] butane, bismaleimidohexane, and bis-N-maleimido-1, 8-octane; the bifunctional aryl halides l,5-difluoro-2,4-dinitiObenzene and 4 5 4'-difluoro-3,3'-dinitrophenylsulfone; bifunctional photoreactive agents such as bis-[b-(4-azidosal
  • SMCC succinimidyl-4-(N-maleimidomethyl)cyclohexane-l-carboxylate
  • MBS m-maleimidobenzoyl-N-hydroxysuccinimide ester
  • Crosslinking may be accomplished by coupling a carbonyl group to an amine group or to a hydrazide group by reductive animation.
  • at least one polypeptide TLR4 ligand and at least one antigen are linked through polymers, such as PEG, poly-D-lysine, polyvinyl alcohol, polyvinylpyrollidone, immunoglobulins, and copolymers of D-lysine and D- glutamic acid.
  • Conjugation of a polypeptide TLR4 ligand and an antigen to a polymer linker may be achieved in any number of ways, typically involving one or more crosslinking agents and functional groups on the polypeptide TLR4 ligand and the antigen.
  • the polymer may also be derivatized to contain functional groups if it does not already possess appropriate functional groups.
  • the vaccines of the invention comprise a fusion protein, wherein the fusion protein comprises at least one polypeptide TLR4 ligand of the invention and at least one polypeptide antigen.
  • the polypeptide TLR4 ligand: antigen fusion protein is obtained by in vitro synthesis of the fusion protein. Such in vitro synthesis may be performed according to any methods well known in the art (see the Section Preparation of the polypeptide TLR4 ligands of the invention: In vitro chemical synthesis, above).
  • the polypeptide TLR4 ligand:antigen fusion protein is obtained by translation of a nucleic acid sequence encoding the fusion protein.
  • a nucleic acid sequence encoding a polypeptide TLR4 ligandrantigen fusion protein- may be obtained by any of the synthetic or recombinant DNA methods well known in the art. See, for example, Glover, DNA Cloning: A Practical Approach 2 nd Edition. Volumes I-IV.
  • Translation of a nucleic acid sequence encoding a polypeptide TLR4 ligand may be achieved by any of the in vitro or in vivo methods well known in the art (see the Section Preparation of the polypeptide TLR4 ligands of the invention: Translation from coding sequences, above).
  • compositions and vaccines are well-known to those of ordinary skill in the art (see, e.g., Remington's Pharmaceutical Sciences, 18 th Edition, Gennaro, ed. (Mack Publishing Company: 1990)).
  • the vaccines of the invention are administered, e.g., to human or non-human animal subjects, in order to stimulate an immune response specifically against the antigen and preferably to engender immunological memory that leads to mounting of a protective immune response should the subject encounter that antigen at some future time.
  • the vaccines of the invention comprise at least one polypeptide TLR4 ligand and at least one antigen, and optionally a pharmaceutically acceptable earner.
  • pharmaceutically acceptable refers to molecular entities and compositions that are "generally regarded as safe", e.g., that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human.
  • pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
  • carrier refers to a diluent, excipient, or vehicle with which the compound is administered.
  • Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
  • suitable carriers include polypeptides (e.g., keyhole limpet hemocyanin (KLH)), liposomes, insoluble salts of aluminum (e.g. aluminum phosphate or aluminum hydroxide), polynucleotides, polyelectrolytes, and water soluble carriers (e.g. muramyl dipeptides).
  • Water or aqueous solution saline solutions and aqueous dextrose and glycerol solutions are preferably employed as earners, particularly for injectable solutions.
  • Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences” by E. W. Martin.
  • the vaccines of the invention vaccines combine both signals required for the induction of a potent antigen-specific adaptive immune response: an innate immune system signal (i.e. TLR4 signaling), and an antigen receptor signal.
  • TLR4 signaling an innate immune system signal
  • antigen receptor signal an antigen receptor signal.
  • the vaccines of the invention are formulated without conventional adjuvants.
  • the invention also contemplates vaccines comprising at least one polypeptide TLR4 ligand and at least one antigen, wherein the vaccine additionally comprises an adjuvant.
  • adjuvant refers to a compound or mixture that enhances the immune response to an antigen.
  • An adjuvant can serve as a tissue depot that slowly releases the antigen and also as. a lymphoid system activator that non-specifically enhances the immune response (Hood et al., Immunology, Second Ed, 1984, Benjamin/Cummings: Menlo Park, California, p. 384).
  • Adjuvants include, but are not limited to, complete Freund's adjuvant, incomplete Freund's adjuvant, saponin, mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil or hydrocarbon emulsions, keyhole limpet hemocyanins, and potentially useful human adjuvants such as N-acetyl-muramyl-L-tlireonyl-D-isoglutamine (thr-MDP), N-acetyl- nor-muramyl-L-alanyl-D-isoglutamine, N-acetylrauramyl-L-alanyl-D-isoglutaminyl- L-alanine-2 ⁇ (r-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine,
  • Vaccine administration can be oral, parenteral (intramuscular, intraperitoneal, intravenous (IV) or subcutaneous injection), transdermal (either passively or using iontophoresis or electroporation), transmucosal (nasal, vaginal, rectal, or sublingual) routes of administration or using bioerodible inserts and can be formulated in dosage forms appropriate for each route of administration. Moreover, the administration may be by continuous infusion or by single or multiple boluses.
  • the vaccine formulations may include diluents of various buffer content (e.g., Tris-HCl, acetate, phosphate), pH and ionic strength; additives such as detergents and solubilizing agents (e.g., Tween 80, Polysorbate 80), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimersol, benzyl alcohol) and bulking substances (e.g., lactose, mannitol); incorporation of the material into particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc. or into liposomes. Hylauronic acid may also be used. See, e.g., Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, PA 18042).
  • additives e.g., Tween 80, Polysorbate 80
  • anti-oxidants e.g., ascorbic acid, sodium metabis
  • the vaccines may be formulated so as to control the duration of action of the vaccine in a therapeutic application.
  • controlled release preparations can be prepared through the use of polymers to complex or adsorb the vaccine.
  • biocompatible polymers include matrices of poly(ethylene-co- vinyl acetate) and matrices of a polyanhydride copolymer of a stearic acid dimer and sebacic acid. (Sherwood et al. Bio/Technology 1992; 10: 1446). The rate of release of the vaccine from such a matrix depends upon the molecular weight of the construct, the amount of the construct within the matrix, and the size of dispersed particles. (Saltzman el al. Biophys.
  • the vaccine can also be conjugated to polyethylene glycol (PEG) to improve stability and extend bioavailability times (e.g., Katre et al.; U.S. Pat. No. 4,766,106).
  • PEG polyethylene glycol
  • Contemplated for use herein are oral solid dosage forms, which are described generally in Remington's Pharmaceutical Sciences, 18th Ed. 1990 (Mack Publishing Co. Easton PA 18042) at Chapter 89, which is herein incorporated by reference.
  • Solid dosage forms include tablets, capsules, pills, troches or lozenges, cachets, pellets, powders, or granules.
  • liposomal or proteinoid encapsulation may be used to formulate the present compositions (as, for example, proteinoid microspheres reported in U.S. Patent No. 4,925,673).
  • Liposomal encapsulation may be used and the liposomes may be derivatized with various polymers (e.g., U.S. Patent No. 5,013,556).
  • a description of possible solid dosage forms for the therapeutic is given by Marshall, K. In: Modern Pharmaceutics Edited by G.S. Banker and CT. Rhodes Chapter 10, 1979, herein incorporated by reference.
  • the formulation will include the therapeutic agent and inert ingredients which allow for protection against the stomach environment, and release of the biologically active material in the intestine.
  • liquid dosage forms for oral administration including pharmaceutically acceptable emulsions, solutions, suspensions, and syrups, which may contain other components including inert diluents; wetting agents, emulsifying and suspending agents; and sweetening, flavoring, coloring, and perfuming agents.
  • the location of release may be the stomach, the small intestine (the duodenum, the jejunem, or the ileum), or the large intestine.
  • the release will avoid the deleterious effects of the stomach environment, either by protection of the therapeutic agent or by release of the therapeutic agent beyond the stomach environment, such as in the intestine.
  • a coating impermeable to at least pH 5.0 is essential.
  • cellulose acetate trimellitate hydroxypropylmethylcellulose phthalate
  • HPMCP 50 hydroxypropylmethylcellulose phthalate
  • HPMCP 55 polyvinyl acetate phthalate
  • PVAP polyvinyl acetate phthalate
  • Eudragit L30D Aquateric, cellulose acetate phthalate (CAP), Eudragit L, Eudragit S, and Shellac.
  • CAP cellulose acetate phthalate
  • Shellac Shellac
  • a coating or mixture of coatings can also be used on tablets, which are not intended for protection against the stomach. This can include sugar coatings, or coatings which make the tablet easier to swallow.
  • Capsules may consist of a hard shell (such as gelatin) for delivery of dry therapeutic (i.e. powder), for liquid forms a soft gelatin shell may be used.
  • the shell material of cachets could be thick starch or other edible paper.
  • moist massing techniques can be used.
  • the formulation of the material for capsule administration could also be as a powder, lightly compressed plugs, or even as tablets. These therapeutics could be prepared by compression. One may dilute or increase the volume of the therapeutic agent with an inert material.
  • diluents could include carbohydrates, especially mannitol, ⁇ -lactose, anhydrous lactose, cellulose, sucrose, modified dextrans and starch. Certain inorganic salts may be also be used as fillers including calcium triphosphate, magnesium carbonate and sodium chloride. Some commercially available diluents are Fast-Flo, Emdex, STA-Rx 1500, Emcompress and Avicell.
  • Disintegrants may be included in the formulation of the therapeutic agent into a solid dosage form.
  • Materials used as disintegrates include but are not limited to starch, including the commercial disintegrant based on starch, Explotab, Sodium starch glycolate, Amberlite, sodium carboxymethylcellulose, ultramylopectin, sodium alginate, gelatin, orange peel, acid carboxymethyl cellulose, natural sponge and bentonite may all be used.
  • the disintegrants may also be insoluble cationic exchange resins.
  • Powdered gums may be used as disintegrants and as binders, and can include powdered gums such as agar, Karaya or tragacanth. Alginic acid and its sodium salt are also useful as disintegrants.
  • Binders may be used to hold the therapeutic agent together to form a hard tablet and include materials from natural products such as acacia, tragacanth, starch and gelatin. Others include methyl cellulose (MC), ethyl cellulose (EC) and carboxymethyl cellulose (CMC). Polyvinyl pyrrolidone (PVP) and hydroxypropylmethyl cellulose (HPMC) could both be used in alcoholic solutions to granulate the peptide (or derivative).
  • MC methyl cellulose
  • EC ethyl cellulose
  • CMC carboxymethyl cellulose
  • PVP Polyvinyl pyrrolidone
  • HPMC hydroxypropylmethyl cellulose
  • Lubricants may be used as a layer between the therapeutic agent and the die wall, and these can include but are not limited to; stearic acid including its magnesium and calcium salts, polytetrafluoroethylene (PTFE), liquid paraffin, vegetable oils and waxes. Soluble lubricants may also be used such as sodium lauryl sulfate, magnesium lauryl sulfate, polyethylene glycol of various molecular weights, Carbowax 4000 and 6000. Glidants that might improve the flow properties of the therapeutic agent during formulation and to aid rearrangement during compression might be added.
  • the glidants may include starch, talc, pyrogenic silica and hydrated silicoaluminate.
  • a surfactant might be added as a wetting agent.
  • Surfactants may include anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate.
  • anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate.
  • Cationic detergents might be used and could include benzalkonium chloride or benzethomium chloride.
  • the list of potential nonionic detergents that could be included in the formulation as surfactants are lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and 60, glycerol monostearate, polysorbate 40, 60, 65 and 80, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose.
  • These surfactants could be present in the formulation of the therapeutic agent either alone or as a mixture in different ratios.
  • Controlled release oral formulations may be desirable.
  • the therapeutic agent could be incorporated into an inert matrix which permits release by either diffusion or leaching mechanisms, e.g., gums. Slowly degenerating matrices may also be incorporated into the formulation.
  • Some enteric coatings also have a delayed release effect.
  • Another form of a controlled release is by a method based on the Oros therapeutic system (Alza Corp.), i.e. the therapeutic agent is enclosed in a semipermeable membrane which allows water to enter and push agent out through a single small opening due to osmotic effects.
  • Oros therapeutic system Alza Corp.
  • coatings may be used for the formulation. These include a variety of sugars which could be applied in a coating pan.
  • the therapeutic agent could also be given in a film coated tablet and the materials used in this instance are divided into 2 groups.
  • the first are the nonenteric materials and include methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, methylhydroxy-ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl-methyl cellulose, sodium carboxy-methyl cellulose, providone and the polyethylene glycols.
  • the second group consists of the enteric materials that are commonly esters of phthalic acid. A mix of materials might be used to provide the optimum film coating.
  • Film coating may be carried out in a pan coater or in a fluidized bed or by compression coating.
  • Vaccines according to this invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions.
  • non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate.
  • Such dosage forms may also contain adjuvants, preserving, wetting, emulsifying, and dispersing agents. They can also be manufactured using sterile water, or some other sterile injectable medium, immediately before use.
  • the ordinary skilled practitioner considering the therapeutic context, age, and general health of the recipient, will be able to ascertain proper dosing.
  • the selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment desired.
  • the dosing schedule may vary, depending on the circulation half-life, and the formulation used.
  • the vaccines of the present invention may be administered in conjunction with one or more additional active ingredients, pharmaceutical compositions, or vaccines.
  • Methods to stimulate an immune response comprising administering to a subject in need thereof a pharmaceutical composition comprising a polypeptide TLR.4 agonist ligand or TLR4 ligand:antigen vaccine of the invention.
  • the subject is a mammal.
  • the subject is a human.
  • the polypeptide TLR4 agonist ligands or vaccines of the invention may be administered to subjects, e.g., mammals including humans, in order to stimulate an antigen-specific immune response and preferably to engender immunological memory that leads to mounting of a protective immune response should the subject encounter that antigen at some future time.
  • the TLR4 agonist ligands of the invention may be used as a nonspecific immunostimulant.
  • Nonspecific immunostimulation may be desirable in the event of a pandemic or bioterrorist attack, in the treatment of cancer, or in the treatment of immune suppression such as occurs in certain infections (e.g., HIV) or as a result of therapeutic treatment (e.g., certain cytotoxic cancer therapeutics).
  • Stimulation of an immune response in a subject can be measured by standard tests including, but not limited to, the following: detection of antigen- specific antibody responses, detection of antigen specific T-cell responses, including cytotoxic T-cell responses, direct measurement of peripheral blood lymphocytes; natural killer cell cytotoxicity assays (Provinciali et al. J. Immunol. Meth.
  • the invention also provides methods to inhibit, or antagonize, an immune response comprising administering to a subject in need thereof a polypeptide TLR.4 antagonist ligand of the invention.
  • the subject is a mammal.
  • the subject is a human.
  • Assays for identifying ligands that have activity as TLR4 antagonists are described in Example 8.
  • the present invention includes methods for administering to a subject a pharmaceutical composition comprising a polypeptide TLR4 antagonist ligands of the invention, in order to antagonize TLR4 and treat an inflammatory disease or disorder.
  • the subject may be a mammals including a human.
  • inflammatory diseases or disorders include, but are not limited to, acute infection, acute phase response, inflammatory bowel disease, ulcerative colitis, Crohn's disease, leukocyte adhesion deficiency II syndrome, peritonitis, chronic obstructive pulmonary disease, lung inflammation, asthma, septic shock, nephritis, amyloidosis, rheumatoid arthritis, chronic bronchitis, sarcoidosis, scleroderma, Systemic Lupus Erythematosus, polymyositis, Reiter's syndrome, psoriasis, pelvic inflammatory disease, multiple sclerosis, inflammatory breast disease, orbital inflammatory disease, and autoimmune disorders.
  • the TLR4 antagonist ligands of the invention may also be used to treat or prevent graft versus host disease or transplant rejection in a subject.
  • the invention provides a method for preventing in a subject, an inflammatory disease or disorder.
  • Subjects at risk for an inflammatory disease or disorder can be identified by, for example, any or a combination of diagnostic or prognostic assays known in the art.
  • Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of an inflammatory disease or disorder, such that an inflammatory disease or disorder is prevented or, alternatively, delayed in its progression.
  • polypeptide TLR4 antagonist ligands of the invention may be used alone or in combination with one or more additional anti-inflammatory agents including, but not limited to, non-steroidal anti-inflammatory agents (e.g., NSAIDS), aspirin, corticosteroids, selective COX-2 inhibitors, interleukin-1 antagonists, dihydroorotate synthase inhibitors, p38 MAP kinase inhibitors, TNF- ⁇ inhibitors, TNF- ⁇ sequestration agents, and methotrexate.
  • non-steroidal anti-inflammatory agents e.g., NSAIDS
  • aspirin e.g., aspirin
  • corticosteroids selective COX-2 inhibitors
  • interleukin-1 antagonists e.g., interleukin-1 antagonists
  • dihydroorotate synthase inhibitors e.g., p38 MAP kinase inhibitors
  • TNF- ⁇ inhibitors e.g., TNF- ⁇ sequestration agents
  • EXAMPLE 1 IDENTIFICATION OF CELL LINES FOR USE IN TLR4
  • HEK293 cells ATCC Accession # CRL-
  • HEK293-null cells Invivogen; cat. # 293-null
  • HEK293:hTLR4A/MD2- CD14 cells Invivogen; cat. #293-htlr4md2cdl4
  • Dulbecco's Modified Eagle Medium Gibco
  • Fetal Bovine Serum Hyclone
  • TLR4 activity assay with LPS Cells were plated at a density of 50,000 cells/well in a 96-well tissue culture plate (Falcon) in the growth media described above. Serially diluted concentrations of Ultrapure LPS (Invivogen; cat. # tlrl-pelps), ranging from 50 ⁇ g to 50 ng, were added to the cells. Cell supernatants were harvested 16-20 hours later. To detect secreted IL-8, a capture ELISA was performed. First, ELISA plates (Costar; cat. # 9018) were coated with anti-IL-8 capture antibody (Pierce; cat. #M801) and stored at 4 0 C overnight.
  • Ultrapure LPS Invivogen; cat. # tlrl-pelps
  • HEK293 cells do not express TLR4 niRNA transcripts.
  • HEK293 cells engineered to stably express human TLR4 isoform A and human CD 14 and MD2 (HEK293:hTLR4A/MD2-CD14) were obtained from Invivogen (catalog # 293- htlr4md2cdl4).
  • HEK293 cells stably transfected with the empty expression construct HEK293-null were obtained from Invivogen (catalog # 293- null). These cells do not express TLR4.
  • TLR4 expressing and non-expressing cells were assessed by quantitating IL-8 secretion of each cell type following exposure to the TLR4 ligand LPS.
  • HEK293-null cells Invivogen; cat. # 293 -null
  • the HEK293:hTLR4A/MD2-CD14 cells are responsive to LPS stimulation (see Figure 3).
  • variable region was generated using an extension reaction.
  • Random oligonucleotides were ordered PAGE purified from The Midland Certified Reagent Company. An EcoRI restriction enzyme site on the 5' end and a HindIII site on the 3' end were included for cloning purposes. In addition, the 3 s end contained additional flanking nucleotides creating a "handle".
  • the random oligonucleotide was 5'-CAT GCC CGG AAT T CC TGC NNK NNK NNK NNK NNK NNK NNK NNK NNK NNK NNK NNK NNK TGC GGA GGA T AA AAG CTT TCG AGA C-3 ' (SEQ ID NO: 50).
  • the random oligonucleotide was 5'-CAT GCC CGG AAT TCC TGC NNK NNK NNK NNK NNK NNK NNK NNK TGC GGA GGA TAA AAG CTT TCG AGA C-3' (SEQ ID NO: 51).
  • a universal oligonucleotide, 5'-GTC TCG AAA GCT TTT ATC CTC C'3' (SEQ ID NO: 52) containing a HindIII site (underlined) was ordered PAGE purified from The Midland Certified Reagent Company.
  • This universal oligonucleotide was annealed to the 3 ' "handle" serving as a primer for the extension reaction.
  • the annealing reaction was performed as follows: 5 ⁇ g of random oligonucleotide were mixed with 3 molar equivalents of the universal primer in dHaO with 10OmM NaCl. The mixture was heated to 95 0 C for two minutes in a heat block. After that time, the heat block was turned off and allowed to cool to room temperature.
  • the annealed oligonucleotides were then added to an extension reaction mediated by the Klenow fragment of DNA polymerase I (New England Biolabs).
  • the extension reaction was performed at 37 0 C for 10 minutes, followed by an incubation at 65 °C for 15 minutes to inactivate the Klenow.
  • the extended duplex was digested with 5OU of both EcoRI (New England Biolabs) and HindIII (New England Biolabs) for 2 hours at 37 0 C.
  • the digested products were separated by polyacrylamide gel electrophoresis, the bands of the correct size were excised from the gel, placed in 500 ⁇ l of elution buffer (1OmM magnesium acetate, 0.1%SDS, 50OmM ammonium acetate) and incubated overnight, with shaking, at 37°C. The following day the eluted DNA was purified by phenol -.chloroform extraction followed by a standard ethanol precipitation.
  • the purified insert was ligated into T7 Select Vector anus (Novagen; cat. # 70548), using 0.6 " Weiss Units of T4 DNA ligase (New England Biolabs). The entire ligation reaction was added to T7 Packaging Extract as per manufacturer's protocol (Novagen; cat. #70014). Using the bacterial strain 5615 (Novagen), the titer of the initial library was determined by a phage plaque assay (Novagen; T7Select System). Both the 7-mer and 10-mer cyclic peptide libraries have 5x10 8 individual clones which approaches the upper achievable limit of the phage display system.
  • Constrained peptide libraries were constructed by inserting a flanking cysteine residue at both the N and C terminus of the random peptide sequence (Cys-N (X )-Cys).
  • the two cysteines form a disulfide bond that forces the random sequence into a loop or cyclic structure. This cyclization restricts conformational freedom, stabilizing the functional presentation of the peptide and potentially improving the binding affinity for target sites due to a reduction in entropy.
  • Two cyclic libraries (7-raer and 10-mer random peptide libraries) were generated using an extension strategy as described in Figure 4. The peptide insert was PCR amplified and sequenced from 96 phage clones from the 7-mer and the 10- mer random peptide libraries. Sequence analysis confirmed that peptides of the specified length and flanked by cysteines had been successfully cloned into the phage vector.
  • RELIC Receptor LIgand Contacts; http://relic.bio.anl.gov/)
  • RELIC Receptor LIgand Contacts; http://relic.bio.anl.gov/
  • the programs available through RELIC will assist in identifying consensus sequences and motifs that are enriched after selection. Additionally, since unselected libraries typically contain a degree of bias in amino acid representation and distribution, the initial bias of our libraries must be analyzed. To this end, 96 independent phage clones from both the unselected lOmer and 7mer libraries were sequenced and the amino acid representation and diversity within the libraries was determined using RELIC. In the lOmer library, glycine, arginine, and valine are over- represented while residues such as proline, isoleucine, and lysine are under- represented.
  • proline, isoleucine and lysine are also under-represented in the 7mer library, perhaps indicating that these residues are refractory to an enforced cyclic structure.
  • This analysis highlights amino acid bias inherent to the libraries and, hence, will provide critical assistance in determining if motifs identified by phage display screens reflect specificity in target binding or initial library bias.
  • Phage display libraries were screened to identify polypeptide TLR ligands according to the following procedure (see Figure 5).
  • a phage display library was subjected to a first phase of screening in order to reduce non-specific binding (i.e., binding not mediated by the TLR of interest).
  • the phage display library was incubated on a cell suspension of in vitro cultured cells that express minimal amounts of the TLR of interest (TLR 10 ). Phage that did not bind to the TLR 10 cells were retained by collecting the cell culture supernatant containing the unbound phage. This process was repeated once (for a total of two screening cycles) to yield a phage population having reduced non-specific binding.
  • This phage population having reduced non-specific binding as retained at the end of the first phase of screening was then divided into a first phage portion and a second phage portion by dividing the supernatant containing unbound phage into equal halves (by volume).
  • the first phage portion and the second phage portion were then subjected to a second phase of screening in order to produce a phage population enriched for specific binding to the target TLR.
  • the first phage portion was incubated on a cell suspension of in vitro cultured cells that express the relevant TLR (TLR hl ) in order to capture phage with binding specificity for the target TLR, and the second phage portion was incubated on in vitro cultured cells that express minimal amounts of the TLR of interest (TLR 10 ) in order to capture phage with non-specific binding.
  • the phage of the first phage portion that bound to the TLR h( cells and the phage of the second phage portion that bound to the TLR 10 cells were each simultaneously retained and amplified by direct liquid amplification in E.coli (strain 5615).
  • the amplified phage of the first phage portion and the amplified phage of the second phage portion were each titered to determine the number of phage in each amplified portion.
  • the amplified phage portions were then used for a subsequent round of screening following the same steps. This screening process was repeated three times (for a total of four screening cycles in the second phase of screening).
  • the number of retained phage of the first phage portion and the number of retained phage of the second phage portion were plotted on a line graph to provide a round-by-round comparison of the number of phage recovered.
  • the number of retained phage of the second phage portion provides a measurement of the number of phage having non-specific binding recovered in the screening assay.
  • the subsequently amplified first phage portion represents a phage population enriched for specific binding to a TLR.
  • Phage display libraries were enriched for those phage that display peptides that specifically mediate TLR-binding by a combined negative screening plus positive screening method as outlined in Figure 5. This method combined a first phase of negative screening with a second phase of positive screening to yield a phage population enriched for specific binding to TLR.
  • EXAMPLE 4 SCREENING ASSAY TO IDENTIFY A PHAGE POPULATION ENRICHED FOR SPECIFIC BINDING TO TLR4
  • Generation of random peptide phage display libraries Constrained 7- mer and 10-mer cyclic peptide phage display libraries were generated as described in EXAMPLE 2, above.
  • Generation of phage displaying an S ⁇ Tag polypeptide The S-tag nucleotide sequence is 5'-ATG AAA GAA ACC GCT GCT GCT AAA TTC GAA CGC CAG CAC ATG GAC AGC CCA-3' (SEQ ID NO: 53).
  • the S-tag amino acid sequence is MKETAAAKFERQHMDSP (SEQ ID NO: 54). Double stranded DNA encoding the S-tag peptide sequence was ligated to the T7Select 10-3 bacteriophage vector (Novagen).
  • the ligation reactions were packaged in vitro and titered using the host E. coli strain BLR5615 that was grown in M9TB (Novagen). The recombinant phage was then amplified. Ligation, packaging, and amplification were performed according to manufacturer's instructions.
  • Mid-scale phage lysates To amplify phage libraries for use in a whole cell screening assay, the packaged phage extracts described above were added to 1OmL of 5615 bacteria (Novagen) at OD 60 O 0.6 and placed in a 37 0 C shaking incubator until lysis was observed (approximately 2 hours). The phage lysate was clarified by spinning at 8,000*g for 10 minutes. After the spin, the phage lysate supernatant was retained. The phage titer after liquid amplification was reproducibly 10 n pfu/mL.
  • the Luria Broth (LB) buffer of the phage lysate supernatant was exchanged with Dulbecco's Modified Eagle Medium (DMEM; Gibco) as follows: First, 5mL of phage lysate supernatant was added to an Amicon Ultra Centrifugal Filter (Millipore; cat. #UFC903024) and spun at 2000*g for 10 minutes. Following the first spin, two washes with DMEM were performed. Finally, the phage lysates were resuspended in 5mL of DMEM. This procedure does not result in a loss of phage titer.
  • DMEM Dulbecco's Modified Eagle Medium
  • phage display libraries to identify a phage population enriched for specific binding to TLR4: 5x10 6 HEK293 cells (ATCC Accession # CRL- 1573) were harvested, pelleted by centrifugation, and resuspended in 500 ⁇ l of growth media (DMEM+10%FBS). ImL of phage lysate (10-mer library lysate, 7-mer library lysate, or S-Tag phage lysate) in DMEM (total of approximately 10 10 phage) was added to the resuspended cells and the cell and phage mixture was rotated at 4°C for 1 hour.
  • the mixture was spun down at low speed for 5 minutes and the supernatant containing unbound phage was transferred to a second (pelleted) aliquot of 5x10 6 HEK293 cells.
  • the cells were rotated for 1 hour and spun down once more.
  • the supernatant was collected and split in equal halves between 1x10 6 HEK293:hTLR4A/MD2-CD14 cells and lxlO 6 HEK293 cells (ATCC Accession # CRL-1573) resuspended in 500 ⁇ l of growth media.
  • the cells were rotated at 4 0 C for 1 hour and spun down at low speed.
  • the supernatant was removed and the cells washed with DMEM at 4 0 C three times. After the last wash, the cells were resuspended in 500 ⁇ l of DMEM.
  • a small aliquot was used to determine phage titer and the rest was amplified and used to repeat the positive screening. In total, four rounds of positive screening were performed. For each round, phage titer was used to monitor enrichment for TLR-specific phage.
  • Constrained, cyclic random peptide (10-mer and 7-mer) phage display libraries were screened for polypeptide TLR4 ligands according to the procedure describe in EXAMPLE 3, above.
  • phage lysate of an S-Tag phage was also screened according to this procedure.
  • the 10-mer phage display library After four rounds of positive screening on TLR4 expressing cells, phage titers had increased 5000 fold (see Figure 6). In contrast, after four rounds of positive screening on cells not expressing TLR4, the 10-mer phage display library and the S-Tag phage showed an enrichment of only 700 fold. Thus, the 10-mer phage display library showed enrichment for TLR4- specific phage following four rounds of positive screening on TLR4 expressing cells. Furthermore, the screening method provided a population of phage containing 10-mer random peptide inserts that is enriched for specific binding to TLR4.
  • HEK293-null cells Invivogen; cat. # 293-null
  • HEK293:hTLR4A/MD2-CD14 cells Invivogen; cat. #293-htlr4md2cdl4 cells
  • TLR4+ and TLR4- plates were grown overnight on poly-D-lysine coated 96- well plates (BD Biosciences) to yield TLR4+ and TLR4- plates, respectively.
  • an individual phage isolate was added to parallel wells of both the TLR4+ and TLR4- plates.
  • TLR4-speci ⁇ c binding The binding specificity of each phage isolate was determined by: 1) averaging the values of duplicate samples and standard curve values; 2) determining a phage titer for each isolate based on the standard curve; 3) subtracting the phage titer from the negative control S-Tag phage from the phage titers obtained with phage isolates; and 4) dividing the TLR4+ titer by the relevant TLR4- titer.
  • a TLR4+:TLR4- ratio of 1 indicates equal binding on to both cell types by the phage isolate, i.e., a lack of specificity, while a value greater than 1 indicates specificity for TLR4+ cells.
  • Randomly picked individual phage clones from phage populations enriched for specific binding to TLR4 were isolated via plaque formation in E. coli, their nucleic acid inserts sequenced, and their binding specificity for TLR4 quantitated using the whole cell ELISA assay.
  • 96 randomly selected phage clones from the enriched phage population of the 10-mer phage display library were isolated, their nucleic acid inserts sequenced to determine the amino acid sequence of the encoded peptide, and their binding specificity quantitated.
  • 18 showed specificity for binding to TLR4 (i.e., a TLR4+:TLR4- binding ratio > 1).
  • the amino acid sequence of the peptide insert and the TLR4+.TLR4- binding ratio for these phage clones are given in Table 2.
  • D7 GMLSLALF (SEQ ID NO: 5) 1.45
  • the peptide insert sequence is shorter than 10 amino acids due to the presence of a stop codon in the encoding nucleic acid insert.
  • 96 randomly selected phage clones from the enriched phage population of the 7-mer phage display library were isolated, their nucleic acid inserts sequenced to determine the amino acid sequence of the encoded peptide, and their binding specificity quantitated.
  • 18 showed specificity for binding to TLR4 (i.e., a TLR4+.-TLR4- binding ratio > 1).
  • the amino acid sequence of the peptide insert and the TLR4+:TLR4- binding ratio for these phage clones are given in Table 3.
  • the peptide insert sequence is shorter than 7 amino acids due to the presence of a stop codon in the encoding nucleic acid insert.
  • Table 2 and Table 3 confirm that the phage population enriched for specific binding to TLR4, as identified by the screening method of the invention, contains individual phage having specificity of binding for TLR4.
  • the peptide inserts of the individual phage having specificity of binding for TLR4 are polypeptide TLR4 ligands. These peptide inserts have been identified as polypeptide TLR4 ligands.
  • EXAMPLE 6 IDENTIFICATION OF POLYPEPTIDE TLR4 LIGANDS: CHARACTERIZATION OF PHAGE ISOLATES BY PHAGE CAPTURE
  • the coding region of the E. coli fiagellin (/7/C) gene (SEQ ID NO: 96) was cloned into the T7SELECT phage display vector (Novagen)* Double stranded DNA encoding E. coli fliC was ligated to the T7Select 10-3 bacteriophage vector (Novagen), The ligation reactions were packaged in vitro and titered using the host E. coli strain BLR5615 that was grown in M9TB (Novagen). The recombinant phage was then amplified. Ligation, packaging, and amplification were performed according to manufacturer's instructions. This phage displays the E.
  • Phage capture assay 96 well plates coated with a monoclonal antibody against the tail fiber of T7 phage (Novagen; cat. # 75131) were blocked with BD Assay Diluent (BD; cat #555213) and then incubated with an individual phage isolate at 37°C. Plates were then washed extensively with PBS containing 0.05% Tween and 50 ⁇ g/mL polymyxin B (Invivogen, cat. #tlrl-pmb) to remove endotoxin.
  • HEK293- null cells Invivogen; cat. # 293-null
  • HEK293:hTLR4A/MD2-CD14 cells Invivogen; cat. #293-htlr4md2cdl4 cells
  • tissue culture media containing polymyxin B
  • the cell culture supernatants were harvested the following day and an ELISA for IL-8 was performed (as described in EXAMPLE 5, above) to assess TLR4-dependent activation of the cells.
  • the detergent wash steps and the inclusion of polymyxin B at each step was essential for reducing the endotoxin in the phage lysates to allow for an observation of peptide-specific signal.
  • TLR4-specific binding i.e., a TLR4+:TLR4- binding ratio >1
  • TLR4-specific binding i.e., a TLR4+:TLR4- binding ratio >1
  • the ability of a phage isolate to function as a TLR4 agonist was quantitated based upon the induction of IL-8 secretion (in pg/ml) by cells expressing TLR4 upon exposure to the phage isolate.
  • the tested phage isolates and their agonist activity on cells expressing TLR4, expressed as IL-8 secretion in pg/ml, are given in Table 4 and Table 5.
  • a measure of IL-8 secretion by cells not expressing TLR4 served as a negative control. Cells not expressing TLR4 were not activated by any of the phage isolates tested (i.e., secreted less than 100 pg/ml of IL-8 in response to each of the phage isolates).
  • Table 5 7-mer phage isolates and agonist activity values
  • D2 and the 7-mer phage isolates C8, C9, D9, C2, G6, GlO 3 A6 and D8 each showed TLR4 agonist activity greater than that of the FIiC negative control phage isolate.
  • the 10-mer phage isolate and the 7-mer phage isolates C8, C9, and D9 showed TLR4 agonist activity at least 2-fold greater than that of the FIiC negative control.
  • this agonist activity is specific to TLR4, as it is not observed when cells not expressing TLR4 are exposed to the phage isolates.
  • A2 and G4 and the 7-mer phage isolates F9, FlO, H5, F6, and B8 do not have measurable TLR4 agonist activity. It is possible that these phage isolates act as TLR4 antagonists. Similarly, it is possible that the peptide inserts of the 10-mer phage isolates A2 and G4 and the 7-mer phage isolates F9, FlO, H5, F6, and B8 are polypeptide TLR4 ligands having TLR4 antagonist activity.
  • EXAMPLE 7 CHARACTERIZATION OF POLYPEPTIDE TLR4 LIGANDS BY ENDOTOXIN FREE BIOACTIVITY ASSAYS
  • Synthetic polypeptide TLR4 ligands The following synthetic peptides were synthesized by BaChem: RNS-CEDMVYRIGVPC-G 4 -H 4 (SEQ ID NO: 55)
  • RNS-SEDMVYRIGVPS-G 4 -H 4 (SEQ ID NO: 56)
  • RNS-CRDIPGARRQAC-G 4 -H 4 (SEQ ID NO: 57)
  • RNS-CEDMVYRIGVPC-G 4 (SEQ ID NO: 58)
  • polypeptide TLR4 ligands may also be measured using endotoxin-free tests. For such tests, endotoxin-free polypeptide
  • TLR4 ligands are obtained, for example, by cloning and expression of polypeptide
  • TLR4 ligands in an endotoxin-free system such as mammalian cell lines or by in vitro chemical synthesis.
  • RNS-CRDIPGARRQAC-G 4 -H 4 (SEQ ID NO: 57)
  • RNS-CEDMVYRIGVPC-G 4 (SEQ ID NO: 58)
  • the first of these synthetic peptides contains the 10-mer peptide sequence of clone D2 (EDMVYRIGVP, SEQ ID NO: 3) with two flanking cysteines and the 3 to 4 amino acids present at the amino and carboxy ends (respectively) of the peptide in the context of the phage coat of the D2 phage isolate.
  • This first synthetic peptide also contains a 4-His tag (SEQ ID NO: 100) to allow for ease of detection in the detection in the phage capture assay.
  • the second synthetic peptide contains flanking serine residues in the place of the flanking cysteine residues.
  • the third synthetic peptide contains a cyclic lOmer sequence derived from enriched phage isolate F3 (RDIPGARRQA; SEQ ID NO: 59), which does not exhibit TLR4-s ⁇ ecific binding or agonist activity, in place of the D2 10-mer sequence.
  • the fourth synthetic peptide does not contain the His tag.
  • EXAMPLE 8 ASSAYS FOR TLR4 ANTAGONIST ACTIVITY
  • Phage capture assay 96 well plates coated with a monoclonal antibody against the tail fiber of T7 phage (Novagen; cat. # 75131) are blocked with BD Assay Diluent (BD; cat #555213) and then incubated with an individual phage isolate at 37 0 C. At least one well is incubated with a S-Tag phage as a negative control. Plates are then washed extensively with PBS containing 0.05% Tween and 50 ⁇ g/mL polymyxin B (Invivogen; cat. #tlrl-pmb) to remove endotoxin.
  • tissue culture media DMEM, 10% FBS
  • tissue culture media DMEM, 10% FBS
  • 50 ⁇ g/mL polymyxin B 50 ⁇ g/mL polymyxin B
  • HEK293:hTLR4A/MD2-CDl4 cells in tissue culture media containing a known TLR4 agonist such as LPS or the 10-mer D2 phage isolate
  • tissue culture media containing a known TLR4 agonist (such as LPS or the 10-mer D2 phage isolate) are added to each well and incubated overnight at 37°C.
  • the cell culture supernatants are harvested the following day and an ELISA for IL-8 is performed (as described in EXAMPLE 5, above) to assess TLR4-dependent activation of the cells.
  • NF-tcB-dependent luciferase reporter assay An individual phage isolate peptide is monitored for the ability to antagonize TLR4-dependent activation of an NF- ⁇ B-dependent luciferase reporter gene in cell lines expressing TLR4.
  • Cells stably transfected with an NF- ⁇ B luciferase reporter construct may constitutively express TLR4, or may be engineered to overexpress TLR4.
  • Cells seeded in a 96-well microplate are exposed to a known TLR4 agonist (such as LPS or the 10-mer D2 phage isolate) plus an individual phage isolate for four to five hours at 37 0 C.
  • the S- Tag phage isolate serves as a negative control.
  • NF- ⁇ B-dependent luciferase activity is measured using the Steady-Glo Luciferase Assay System by Promega (E2510), following the manufacturer's instructions. Luminescence is measured on a microplate lurninometer (FARCyte, Amersham). Antagonist activity of a phage isolate is expressed as the IC 50 , i.e., the concentration that yields a response that is 50% of the maximal response obtained with the S-Tag control phage. The EC50 values are normalized to protein concentration as determined in the ELISA described above.
  • TLR4 antagonists To determine if individual phage isolates from phage populations enriched for specific binding to TLR4 act as TLR4 antagonists, competition assays will be performed. In such assays, the ability of the individual phage isolates to inhibit induction of IL-8 secretion by a known TLR4 agonist (such as LPS or the 10- mer D2 isolate) is quantitated using the phage capture assay or an NF- ⁇ B-dependent reporter gene assay. In the phage capture assays, those phage isolates that provide for reduced IL-8 secretion (in pg/ml) as compared to the S-Tag phage (negative control) are TLR4 antagonists. In the NF- ⁇ B-dependent reporter gene assay, those phage isolates that provide for reduced luciferase activity as compared to the S-Tag phage (negative control) are TLR4 antagonists
  • FlO, H5, F6, and B8 are tested in these assays to quantitate their activity as TLR4 antagonists.
  • Duplicate samples are subjected to PCR using phage specific primers, T7FOR (5'-GAA TTG TAA TAC GAC TCA CTA TAG GGA GGT GAT GAA GAT ACC CCA CC-3'; SEQ ID NO: 60), and T7REV (5'-TAA TAC GAC TCA CTA TAG GGC GAA GTG TAT CAA CAA GCT GG-3'; SEQ ID NO: 61) that flank the phage inserts.
  • T7FOR 5'-GAA TTG TAA TAC GAC TCA CTA TAG GGA GGT GAT GAA GAT ACC CCA CC-3'; SEQ ID NO: 60
  • T7REV 5'-TAA TAC GAC TCA CTA TAG GGC GAA GTG TAT CAA CAA GCT GG-3'; SEQ ID NO: 61) that flank the phage inserts.
  • the forward primer is about 600 bp away from the insert and is designed to incorporate the T7 promoter upstream of the Kozak sequence (KZ), which is critical for optimal translation of eukaryotic genes, and a 6X HIS-tag sequence (SEQ ID NO: 99) (open circle).
  • the reverse primer includes the myc sequence at the c-terminus of the peptide. Therefore, the PCR product will contain all the signals necessary for optimal transcription and translation (T7 promoter, Kozak sequence and the ATG initiation codon), as well as and sequences encoding an N-terminal 6X HIS tag (SEQ ID NO: 99) and a C-terminal myc tag for capture, detection and quantitation of the translated protein.
  • the PCR products are purified using the QlAquick 96 PCR Purification Kit (Qiagen).
  • In vitro TNT Rabbit reticulocyte lysate is programmed with the PCR DNA using TNT T7 Quick for PCR DNA kit (Promega), which couples transcription to translation. To initiate a TNT reaction, the DNA template is incubated at 3O 0 C for 60-90 min in the presence of rabbit reticulocyte lysate, RNA polymerase, amino acid mixture and RNAsin ribonuclease inhibitor.
  • Immunoanalysis of the in vitro translated protein is used to confirm translation of the polypeptide TLR4 ligand.
  • an aliquot of the TNT reaction is analyzed by western blot using antibodies specific for one of the engineered tags, or by ELISA to allow normalization for protein levels across multiple samples.
  • 6X HIS-tagged (SEQ ID NO: 99) protein is captured on Ni-NTA microplates and detected with an antibody to one of the heterologous tags (i.e., anti-c-myc).
  • NF ⁇ B-dependent luciferase reporter assay An aliquot of the in vitro synthesized polypeptide TLR4 ligand is monitored for the ability to activate an NF- ⁇ B-de ⁇ endent luciferase reporter gene in cell lines expressing TLR4. Cells stably transfected with an NF- ⁇ B luciferase reporter construct may constitutively express TLR4, or may be engineered to overexpress TLR4. Cells seeded in a 96- well microplate are exposed to test peptide for four to five hours at 37 0 C.
  • NF- ⁇ B-dependent luciferase activity is measured using the Steady-Glo Luciferase Assay System by Promega (E2510), following the manufacturer's instructions. Luminescence is measured on a microplate luminometer (FARCyte, Amersham). Agonist activity of a polypeptide TLR4 ligand is expressed as the EC 50 , i.e., the concentration that yields a response that is 50% of the maximal response obtained with the appropriate control reagent, such as LPS. The EC50 values are normalized to protein concentration as determined in the ELISA described above.
  • Dendritic cell activation assay For this assay murine or human dendritic cell cultures are obtained.
  • Murine DCs are generated in vitro as previously described (Lutz et al. J lmmiin Meth. 1999;223:77-92).
  • bone marrow cells from 6-8 week old C57BL/6 mice are isolated and cultured for 6 days in medium supplemented with 100 U/ml GMCSF, replenishing half the medium every two days.
  • nonadherent cells are harvested and resuspended in medium without GMSCF and used in the DC activation assay.
  • Human DCs are obtained commercially (Cambrex, Walkersville, MD) or generated in vitro from peripheral blood obtained from healthy donors as previously described (Sallusto & Lanzavecchia. J Exp Med 1994;179:1109-1118).
  • peripheral blood mononuclear cells are isolated by Ficoll gradient centrifugation. Cells from the 42.5-50% interface are harvested and further purified following magnetic bead depletion of B and T cells using antibodies to CD 19 and CD2, respectively.
  • the resulting DC enriched suspension is cultured for 6 days in medium supplemented with 100 U/ml GMCSF and 1000 U/ml IL-4. On day 6, nonadherent cells are harvested and resuspended in medium without cytokines and used in the DC activation assay. An aliquot of the in vitro synthesized polypeptide TLR4 ligand is added to DC culture and the cultures are incubated for 16 hours.
  • cytokine IFN ⁇ , TNF ⁇ , IL- 12 ⁇ 70, IL-10 and IL-6 concentrations are determined by sandwich enzyme-linked immunosorbent assay (ELISA) using matched antibody pairs from BD Pharmingen or R&D Systems, following the manufacturer's instructions.
  • ELISA sandwich enzyme-linked immunosorbent assay
  • Cells are harvested, and costimulatory molecule expression (e.g., B7-2) is determined by flow cytometry using antibodies from BD Pharmingen or Southern Biotechnology Associates following the manufacturer's instructions; analysis is performed on a Becton Dickinson FACScan running Cellquest software.
  • TNT reactions are used to generate endotoxin-free polypeptide TLR4 ligands. These endotoxin-free polypeptide TLR4 Hgands are then assessed for TLR4 agonist activity.
  • Ligase independent cloning Individual T7SELECT phage clones from the phage population enriched for specific binding to TLR4 are subjected to PCR to isolate the nucleotide sequences encoding the TLR4-binding peptides.
  • PCR is performed using the primers T7-LICf (5'-GAC GAC GAC AAG ATT GAG ACC ACT CAG AAC AAG GCC GCA CTT ACC GAC C-3'; SEQ ID NO: 62) and T7- LICr (5'-GAG GAG AAG CCC GGT CTA TTA CTC GAG TGC GGC CGC AAG- 3'; SEQ ID NO: 63) at 10 pmol each with phage lysate at 1 :20 dilution using the Taq polymerase master mix (Invitrogen) at 1 :2 dilution.
  • T7-LICf 5'-GAC GAC GAC AAG ATT GAG ACC ACT CAG AAC AAG GCC GCA CTT ACC GAC C-3'
  • T7- LICr 5'-GAG GAG AAG CCC GGT CTA TTA CTC GAG TGC GGC CGC AAG- 3'; SEQ ID NO: 63
  • PCR cycling conditions are as follows: denaturation at 95°C for 5min; 30 cycles of denaturation step at 95°C for30 sec, annealing step at 58 0 C for 30 sec, and extension at 72 0 C for 30sec; and a final extension at 72°C for 1 Omin.
  • LIC ligase independent cloning
  • pET24a-LICf 5'-phosphorylated primers pET24a-LICf
  • pET24a ⁇ LIC-r 5'-TCA GCT GAG GAG AAG CCC GGG CTC TTG TCG TCG TCA TCA TCA TGG TGA TGG TGA TGA TGC A-3'; SEQ ID NO: 65
  • Ndel and J5pw 11021 digested pET24a via cohesive end ligation are annealed and cloned into Ndel and J5pw 11021 digested pET24a via cohesive end ligation.
  • pMT-Bip-LIC is constructed in the same way as pET-LIC24 by inserting an annealed oligonucleotide into BgIII and MwI digested vector pMTBip/V5-HisA, (Invitrogen).
  • the annealed oligonucleotide is made using the 5'- phosphorylated primers pMTBip-LICf (5'-GAT CTC ATC ATC ACC ATC ACC ATG ATG ACG ACG ACA AGA GCC CGG GCT TCT CCT CAA-3'; SEQ ID NO: 66) and pMTBip-LICr (5'-CGC GTT GAG GAG AAG CCC GGG CTC TTG TCG TCG TCA TCA TGG TGA TGG TGA TGA TGA TGA-3'; SEQ ID NO: 67).
  • E. coli strain BLR (DE3) pLysS strain (Invitrogen) is transformed with pET-LIC plasmid DNA using a commercially available kit (Qiagen).
  • a colony is inoculated into 2-ml LB containing 100 ⁇ g/ml carbenicillin, 34 ⁇ g/ml chloramphenicol supplemented with 0.5% glucose and grown overnight at 37 0 C with shaking.
  • a fresh 2-ml culture is inoculated with a 1 :20 dilution of the overnight culture and grown at 37 0 C for several hours until ODeoo — 0.5-0.8. Protein expression is induced by the addition of IPTG to 1 mM for 3 hours.
  • Ni-NTA protein purification E. coli cells transformed with the construct of interest are grown and induced as described above. The cells are harvested by centrifugation (7000 rpm x 7 minutes in a Sorvall RC5C centrifuge) and the pellet re-suspended in lysis Buffer B (100 mM NaH2PO4, 10 mM Tris-HCl, 8 M urea, pH 8 adjusted with NaOH) and 10 mM imidazol. The suspension is freeze- thawed 4 times in a dry ice bath. The cell lysate is centrifuged (40,000 g for one hour in a Beckman Optima L ultracentrifuge) to separate the soluble fraction from inclusion bodies.
  • lysis Buffer B 100 mM NaH2PO4, 10 mM Tris-HCl, 8 M urea, pH 8 adjusted with NaOH
  • the supernatant is mixed with ImI Ni-NTA resin (Qiagen Ni-NTA) that has been equilibrated with buffer B and binding of the proteins is allowed to proceed at 4 0 C for 2-3 h a roller.
  • the material is then loaded unto 1 cm-diameter column.
  • the bound material is then washed 2 times with 30ml wash buffer (Buffer B + 2OmM imidazol).
  • the proteins are eluted in two rounds with 3ml elution buffer twice (Buffer B+250mM imidazol).
  • the eluates are combined and the pools are used to perform a serial dialysis starting with 1 L of buffer (Buffer B + 250 mM imidazol:2x PBS in a ratio of 1 :1) with change in buffer every 4-8 h.
  • the final dialysis step is performed with two changes of PBS overnight. The integrity of the proteins is verified by SDS-PAGE and immunoblot.
  • the protein is chromato graphed through Superdex 200 gel filtration in the presence of 1% deoxycholate to separate protein and endotoxin.
  • a second round of Superdex 200 gel filtration in the absence of deoxycholate removes the detergent from the protein sample.
  • Purified protein is concentrated and dialyzed against Ix PBS, 1% glycerol. The protein is aliquoted and stored at -8O 0 C.
  • Protein expression in Drosophila S-2 cells The pMTBip-LIC vectors are used to direct recombinant peptide expression in Drosophila S-2 cells.
  • Conditioned medium from S-2 cells expressing the recombinant peptide may be directly used in bioassays to confirm the activity of the TLR4-binding peptide.
  • Drosophila S-2 cells and the Drosophila Expression System (DES) complete kit is obtained from Invitrogen (catalog#: K5120-01, K4120-01, K5130-1 and K4130-01). The growth and passaging of the S-2 cells, transfection and harvesting of the conditioned medium are performed according to manufacturer's protocol.
  • HEK293:Null and HEK293:hTLR4A/MD2-CD14 cells are seeded in 96- well microplates (50,000 cells/well), and aliquots of either purified recombinant peptide expressed in E. coli or conditioned medium from S-2 cells expressing recombinant peptide are added.
  • As a positive control cells are incubated with the Ultrapure LPS (Invivogen; cat. #tlrpelps). The microplates are then incubated overnight.
  • the conditioned medium is assayed for the presence of IL-8 in a sandwich ELISA using an anti -human IL- 8 matched antibody pair (Pierce, catalog # M801E and # M802B) following the manufacturer's instructions.
  • Optical density is measured using a microplate spectrophotometer (FARCyte, Amersham).
  • Double stranded DNA encoding the polypeptide TLR4 ligand is ligated upstream of sequences encoding a fusion protein of antigenic MHC class I and II epitopes of L. monocytogenes proteins LLO and p60.
  • the amino acid sequence of the L. monocytogenes LLO-p60 fusion protein is given in SEQ ID NO: 85.
  • These ligated sequences encoding a polypeptide TLR4 ⁇ gm ⁇ :Listeria LLO-p60 antigen fusion protein are inserted into a plasmid expression vector.
  • the expression construct is engineered by using convenient restriction enzyme sites or by PCR.
  • sequences encoding the polypeptide TLR4 ligand are inserted upstream of the LLO-p60 encoding sequence in the expression construct T7.LIST ( Figure 7), where T7.LIST is assembled as described below.
  • the expressed fusion protein will contain both a V5 epitope (GKPIPNPLLGLDST; SEQ ID NO: 49) and a 6xHis tag (SEQ ID NO: 99).
  • LLOF6 5'-CTC GTA AAA GCG AAC TCG GAA TTA GTA GAA-3'; SEQ ID NO: 70
  • P60R7 5' AGA GGT CTC GAG TGT ATT TGT TTT ATT AGC ATT TGT G-3'; SEQ ID NO: 71
  • This PCR serves to mutate the LLO sequence spanned by LL0R3 and LLOF6 so as to remove the EcoRI site.
  • This product is then ligated into the pCRT7CT-TOPO cloning vector (Invitrogen) to generate the T7.LIST plasmid.
  • expression of the chimeric DNA insert is driven by the strong T7 promoter, and the insert is fused in frame to the V5 epitope (GKPIPNPLLGLDST; SEQ ID NO: 49) and polyhistidine (6x His) (SEQ ID NO: 99) is located at the 3' end of the gene (see Figure 7).
  • Protein expression and immunoblot assay In general, the following protocol will be used to produce recombinant polypeptide TLR4 ⁇ igan.d:Listeria LLO- p60 antigen: fusion protein.
  • coli strain BL (DE3) pLysS strain (Invitrogen) is transformed with the desired plasmid DNA using a commercially available kit (Qiagen).
  • a colony is inoculated into 2-ml LB containing 100 ⁇ g/ml carbenicillin, 34 ⁇ g/ml chloramphenicol supplemented with 0,5% glucose and grown overnight at 37 0 C with shaking.
  • a fresh 2-ml culture is inoculated with a 1 :20 dilution of the overnight culture and grown at 37 0 C for several hours until OD 60O ⁇ 0.5-0.8. Protein expression is induced by the addition of IPTG to 1 mM for 3 hours.
  • the bacteria are harvested by centrifugation and the pellet is re-suspended in 100 ⁇ l of Ix SDS-PAGE sample buffer in the presence of ⁇ -mercaptoethanol.
  • the samples are boiled for 5 minutes and 1/10 volume of each sample is loaded onto 10% SDS-PAGE gel and electrophoresed.
  • the samples are transferred to PVDF membrane and probed with ⁇ - His antibody (Tetra His, Qiagen) at 1 :1000 dilution followed by rabbit anti-mouse IgG/ AP conjugate (Pierce) at 1:25,000.
  • the immunoblot is developed using BCIP/NBT colorimetric assay kit (Promega).
  • Polypeptide TLR4 ⁇ igw ⁇ ;Listeria LLO-p60 antigen fusion proteins are expressed with a 6X Histidine tag (SEQ ID NO: 99) to facilitate purification.
  • E. coli cells transformed with the construct of interest are grown and induced as described above. Cells are harvested by centrifugation at 7,000 rpm for 7 minutes at 4 0 C in a Sorvall R.C5C centrifuge. The cell pellet is resuspended in Buffer A (6 M guanidine HCl, 100 mM NaH 2 PO 4 , 10 mM Tris-HCl, pH 8.0). The suspension can be frozen at -8O 0 C if necessary.
  • Cells are disrupted by passing through a microfluidizer at 16,000 psi.
  • the lysate is centrifuged at 30,000 rpm in a Beckman Coulter Optima LE-80K Ultracentrifuge for 1 hour.
  • the supernatant is decanted and applied to Nickel-NTA resin at a ratio of ImI resin/lL cell culture.
  • the clarified supernatant is incubated with equilibrated resin for 2-4 hours by rotating.
  • the resin is washed with 200 volumes of Buffer A.
  • Buffer B 8 M urea, 100 mM NaH 2 PO 4 , 10 mM Tris-HCl, pH 6.3).
  • a second round of Superdex 200 gel filtration in the absence of deoxycholate removes the detergent from the protein sample.
  • Purified protein is concentrated and dialyzed against Ix PBS, 1% glycerol. The protein is aliquoted and stored at -8O 0 C.
  • Endotoxin assay Endotoxin levels in recombinant fusion proteins is measured using the QCL-1000 Quantitative Chromogenic LAL test kit (BioWhittaker #50-648U), following the manufacturer's instructions for the microplate method.
  • Confirmation of TLR4 agonist activity in NF- ⁇ B lucif erase reporter assays Purified recombinant polypeptide TLR4 ⁇ igm ⁇ :Listeria LLO-p ⁇ O antigen fusion proteins are assayed for TLR4 agonist activity and selectively in the NF- ⁇ B- dependent luciferase assay as described above.
  • Sublethal L. monocytogenes challenge Seven days after immunization, BALB/c mice are infected by i.v. injection of 10 3 CFU L. monocytogenes in 0.1 ml of PBS. Spleens and livers are removed 72 hours after infection and homogenized in 5 ml of sterile PBS + 0.05% NP-40. Serial dilutions of the homogenates are plated on BHI agar. Colonies are enumerated after 48 hours of incubation. These experiments are performed a minimum of 3 times utilizing 10-20 animals per group. Mean bacterial burden per spleen or liver is compared between treatment groups by Student's t-Test.
  • mice are infected i.v. (10 5 CFU) or p,o. (10 9 CFU) with L monocytogenes in
  • T-cell responses are monitored at specific time points following vaccination (i.e. day 7, 14, 30,120) by quantitating the number of antigen-specific ⁇ -interferon secreting cells using ELISPOT (R&D Systems).
  • ELISPOT R&D Systems
  • T-cells are isolated from the draining lymph nodes and spleens of immunized animals and cultured in microtiter plates coated with capture antibody specific for the cytokine of interest. Synthetic peptides corresponding to the K d ⁇ restricted epitopes, p602i?-2 2 s and LLO 91 - 99 are added to cultures for 16 hours.
  • CD4 responses are quantified by IL-4 ELISPOT following stimulation with the I-A d restricted CD4 epitopes LLOi s9-2oo, LLO215-227, and p6O 3 oo-3i i- Antigen specific responses are quantified using a dissection microscope with statistical analysis by Student's t-Test.
  • flow cytometric analysis of T cell populations following staining with recombinant MHC Class I tetramer (Beckman Coulter) loaded with the H-2 restricted epitopes noted above.
  • Cytotoxic T-fymphocyte (CTL) responses At specific time points following vaccination (i.e. day 7, 14, 30,120), induction of antigen-specific CTL activity is measured following in vitro restimulation of lymphoid cells from immune and control animals, using a modification of the protocol described by Bouwer and Hinrichs. Briefly, erythiOcyte-depleted spleen cells are cultured with Concanavalin A or peptide-pulsed, mitomycin C-treated syngeneic stimulator cells for 72 hours. Effector lymphoblasts are harvested and adjusted to an appropriate concentration for the effector assay. Effector cells are dispensed into round bottom black microtiter plates.
  • Target cells expressing the appropriate antigen are added to the effector cells to yield a final effector :target ratio of at least 40:1. After a four hour incubation, target cell lysis is determined by measuring the release of LDH using the CytoTox ONE fluorescent kit from Promega, following the manufacturer's instructions.
  • Antibody responses Antigen-specific antibody titers are measured by ELISA according to standard protocols (see, e.g., Cote-Sierra et al. Infect Immun 2002;70:240-248). For example, immunoglobulin isotype titers in the preimmune and immune sera are measured by using ELISA (Southern Biotechnology Associates, Inc., Birmingham, Ala.).
  • 96-well Nunc-Immuno plates (Nalge Nunc International, Roskilde, Denmark) are coated with 0.5 ⁇ g of COOHgp63 per well, and after exposure to diluted preimmune or immune sera, bound antibodies are detected with horseradish peroxidase-labeled goat anti-mouse IgGl and IgG2a.
  • ELISA titers are specified as the last dilution of the sample whose absorbance was greater than threefold the preimmune serum value.
  • antigen-specific antibodies of different isotypes can be detected by Western blot analysis of sera against lysates of whole L. monocytogenes, using isotype-specific secondary reagents.
  • L. monocytogenes is a highly virulent and prevalent food-borne gram- positive bacillus that causes gastroenteritis in otherwise healthy patients (Wing et al. J Infect Dis 2002;185 Suppl 1 :S18-S24), and more severe complications in immunocompromised patients, including meningitis, encephalitis, bacteremia and morbidity (Crum. Ciirr Gastroenterol Rep 2002;4:287-296 and Frye et al. Clin Infect Dis 2002;35:943-949).
  • In vivo models have identified roles for both T- and B-cells in response to L. monocytogenes, with protective immunity attributed primarily to CD 8 cytotoxic T cells (CTL) (Kersiek and Pamer.
  • the polypeptide TLR4 ligands on the invention may be used to generate a fusion protein vaccine for Listeria infection.
  • This vaccine comprises a fusion protein of polypeptide TLR4 ligand and antigenic MHC class I and II epitopes of L. monocytogenes proteins LLO and p60 (Listeria monocytogenes LLO-p60 fusion protein, SEQ ID NO: 85).
  • sequences encoding a polypeptide TLR4 ligeai ⁇ :Listeria LLO-p60 antigen fusion protein are inserted into a plasmid expression vector. The expression construct is then expressed in E. coli and the recombinant fusion protein purified based upon the included His tag.
  • the purified protein is then used to vaccinate mice.
  • animals are examined for antigen-specific humoral and cellular responses, including serum antibody titers, cytokine expression, CTL frequency and cytotoxicity activity, and antigen-specific proliferative responses. Protection versus Listeria infection is confirmed in the vaccinated animals using sublethal and lethal Listeria challenge assays.
  • the polypeptide TLR4 ligand:.Z,w/m ⁇ LLO-p60 antigen fusion protein vaccine provides strong antigen-specific humoral and cellular immune responses, and provides protective immunity versus Listeria infection.
  • EXAMPLE 12 SYNTHETIC PEPTIDES THAT ACT AS TLR4 AGONISTS
  • HEK293 cells Invivogen; cat. # 293-null
  • HEK293:TLR4 cells Invivogen; cat. #293-htlr4md2cdl4
  • RAW267.4 cells (ATCC #TIB-71) were maintained in Dulbecco's Modified Eagle Medium (Gibco) with 10% Fetal Bovine Serum (Hyclone). Cells were passaged 1 :8 every three days.
  • Synthetic Peptides Synthetic peptides were made by a commercial vendor (BaChem) using solid phase synthesis. Peptides were HPLC purified (purity > 95%). Peptides were resuspended in either phosphate buffer saline (PBS) or a formulation buffer developed in-house termed F 12 Ia.
  • the recipe for F 12 Ia is as follows: 10 mM histidine, 10% sucrose (w/v), 1.5% (w/v) polysorbate-80, 0.1 mM EDTA, 0.5% (v/v) ethanol at pH 6.5. Lyophilized peptides are stored at -20C and peptide solutions are made fresh at the start of each experiment.
  • IZiW Bioactivity Assay Cells were plated at a density of 50,000 cells/ well in a 96-well tissue culture plate (Falcon) in growth media described above. Either Ultrapure LPS (Invivogen; cat. # tlrl-pelps) or synthetic peptides were added to the cells. Cell supernatants were harvested 16-20 hours later. IL-8 was used as a readout for cellular activation when HEK293 cells were used and TNF was used with RAW264.7 cells.
  • ELISA To detect IL-8 (HEK cells), a capture ELISA was performed. First, ELISA plates (Costar; cat. # 9018) were coated with anti-IL-8 capture antibody
  • ELISA plates were coated with an anti-TNF capture antibody (BD Pharmingen #557516) in coating buffer (.1M Na 2 HPO 4 adjusted to pH 6.0 with NaH 2 PO 4 ) and incubated overnight at 4°C. The following morning, the capture antibody solution was removed and the blocking solution, BD Assay Diluent, was added to each well and the plates were incubated at room temperature for one hour. The plates were then washed twice with IXPBS + .05% Tween-20 (PBS-T). TNF standard (BD Pharmingen #554589) and samples (in duplicate) were added to the blocked wells and incubated at room temperature for 1 hour. The remaining steps of the ELISA were performed as described for the IL-8 ELISA above.
  • phage isolates have been identified that specifically activate cells expressing human TLR4 (hTLR4), CD 14 and MD2.
  • hTLR4 human TLR4
  • CD 14 and MD2 CD 14 and MD2.
  • TLR4 agonists when removed from the structural confines of the T7 phage coat protein.
  • the peptide sequence (EDMVYRIGVP (SEQ ID NO:3)) derived from the phage isolate D2 described in Example 5, above, was first tested. As shown in Table 6, this peptide contains the insert expressed by the D2 phage isolate including the two flanking cysteines. The three and four amino acids present at the amino and carboxy ends, respectively, of the peptide in the context of the phage coat protein were also included in the synthetic version. Additionally, the peptide contains a 4x-His tag (SEQ ID NO: 100) to allow detection in a binding assay if desired. The three remaining synthetic peptides served as controls. The peptide termed D2.No His is identical to peptide D2 except that the His tag has been removed.
  • peptide D2.Ser Sub contains serine residues in place of the flanking cysteines to test the requirement of the cyclic nature of the peptide for TLR4 activity.
  • peptide F3 contains a cyclic lOmer sequence that does not exhibit TLR4 specific binding or agonist activity ( Figure 9). All four peptides were synthesized by a commercial vendor and the presence of a disulfide bond between the flanking cysteines (peptides 1, 2, and 4) was confirmed by an Elman's assay.
  • D2 acts similarly on mouse and human TLR4 and analyze the activity of D2 in a system that more closely mimics endogenous TLR4 expression levels
  • D2 on the mouse macrophage cell line RAW264.7 which naturally expresses TLR4 was tested. Titrating molar amounts of peptide were added to RAW264.7 cells. Cell supernatants were collected 20 hours later and the presence of TNF was measured by ELISA as a measure of TLR-dependent cell activation. As shown in Figure 9, only D2 and D2-No His activated RAW264.7 cells. This result shows that the cysteine constrained peptide sequence EDMVYRIGVP (SEQ ID NO:3) is able to activate a mouse cell line expressing endogenous levels of TLR4 in vitro. These data mark the first time, to our knowledge, that a synthetic peptide has been shown to activate through TLR4.
  • D2 and F5 two peptides which reproducibly activate TLR4+ cells in vitro. Analysis of multiple hits will provide sequence data for use in peptide optimization. Along this line, D2 and F5 peptides share a three amino acid motif with conserved substitutions, providing insight into a putative activation motif (Table 8). Table 8. Sequence Alignment of Active Peptides. The sequences of D2 and F5 are shown and the shared three amino acid motif is underlined.
  • TLR4+ TLR4+ or C3H/HeJ (TLR4-) mice using a needle and syringe.
  • Cells were washed in RPMI-1640 supplemented with 10% FBS (HyClone). Red blood cells were removed from the suspension using Red Blood Cell Lysis solution (Sigma) as per manufacturer's protocol. The remaining cells were resuspended in Dendritic Cell Growth Media (RPMI- 1640 containing FBS and a 1 : 100 dilution of mouse GM-CSF) to promote differentiation from stem cells to bone marrow derived dendritic cells
  • BMDCs BMDCs
  • Cells were cultured for four days, with media being replenished on day 2 and day 4.
  • the cells have differentiated into BMDCs as indicated by a distinct change in morphology as well as the upregulation of cell surface markers associated with this cell type.
  • C3H/HeN(TLR4+:TLR2+) BMDC and C3H/HeJ(TLR4-:TLR2+) BMDC were stimulated with either Ultrapure LPS (Invivogen; # tlrl-pelps), Pam3CSK4 (Invivogen, #tlrl-pms), or peptides synthesized by a commercial vendor (BaChem). All ligands were resuspended in Ix PBS and added directly to the cells in the 24-well plate. After 18 hours, cell supematants were harvested for analysis.
  • Human CD 14+ monocytes were obtained from a commercial vendor (Cambrex, #2W-400B). Cells were washed with RPMI-1640 (Gibco) supplemented with 10% FBS. Cells were resuspended in RPMI-1640 with FBS and 50ng/mL hGM-CSF (Peprotech, #300-03) and lOOng/mL hIL-4 (R&D Systems, #204-IL) at a concentration of 5x10 5 cells/mL. Cells were plated in 24 well plates and cultured for five days. Media was replenished on day 3 and day 5.
  • D2 amino acid sequence EDMVYRIGVP (SEQ ID NO:3) was identified that activates both an HEK cell line transfected with human TLR4 and the RAW macrophage cell line (mouse origin) that endogenously expresses TLR4.
  • mice bone marrow derived dendritic cells
  • BMDC mouse bone marrow derived dendritic cells
  • Femur bone marrow cells were isolated from C3H/HeN (TLR4+) and C3H/HeJ (TLR null) mice. These cells were cultured in the presence of GM-CSF over four days, ultimately generating immature BMDC as indicated by the upregulation of CDl Ic and moderate levels of MHCII on the cell surface (data now shown).
  • C3H/HeN (TLR4+:TLR2+) BMDC and C3H/HeJ (TLR4- :TLR2+) BMDC were stimulated with 500 ng/mL or 50 ng/mL of LPS (TLR4 ligand, positive control), peptide D2 at 100 ⁇ M or 50 ⁇ M, peptide F3 (negative control) at 100 ⁇ M or 50 ⁇ M, and 500 ng/mL or 50 ng/mL of Pam3Cys (TLR2 ligand). All stimulants were resuspended in Ix PBS. After 18 hours, cell supernatants were harvested for analysis of cytokine/chemokine production.
  • CBA Cytokine Bead Array
  • C3H/HeJ BMDC (TLR2+:TLR4 null) produced high levels of TNF, IL-6 and MCP-I in response to Pam3CSK4 but not LPS or any of the synthetic peptides tested.
  • D2 stimulates mouse BMDC to produce modest levels of inflammatory cytokines in a TLR4 ⁇ specific manner, indicating that this peptide is capable of activating mouse primary cells as well as cell lines.
  • Human Primary Cells It is well established that dendritic cells differentiated from human blood monocytes express TLR4 and are responsive to LPS.
  • Purified CD 14+ monocytes were obtained from a commercial vendor (Cambrex) and were differentiated in complete RPMI media supplemented with 50 ng/mL hGM-CSF and 100 ng/mL hIL-4 for six days. On the sixth day, 100 ng/mL or 10 ng/mL of LPS, 50 ⁇ M or 10 ⁇ M of D2 peptide or F3 (negative control peptide) were added to the cells. In this experiment, the peptides were resuspended in a formulation buffer (Fl 2 Ia) designed to enhance the stability of the peptides. Cell supernatants were collected at 24 and 48 hours post-stimulation.
  • a formulation buffer Fl 2 Ia
  • Phage Capture Bioassay for TLR4 Agonists This example describes some modifications to the phage capture bioassay described above in Example 3 and in Figure 5, and use of the bioassay to identify additional phage isolates with TLR4 agonist activity. First, TLR4- cells were not tested in parallel with TLR4+ cells.
  • Each phage isolates was tested in duplicate. The value of each duplicate was then compared to the average of all isolates tested on a given plate. Isolates that were at least two standard deviations above the plate average, in duplicate, were scored as positive. Phage isolates that scored positive on TLR4+ cells were then tested on the parental HEK:Null (TLR4-) cells to exclude those that non-specifically activate HEK cells.
  • Phage isolates with activity on HEK:TLR4 cells Peptide sequences derived from phage isolates that activate HEK:TLR4 cells are shown. "Isolate OD” refers to the average of the duplicate OD values from each positive isolate. "Avg Control OD +/- S.D.” shows the sample average and standard deviation from the plate on which the corresponding phage isolate was tested. Note that each positive isolate has an average value that is at least 2 standard deviations above the plate average.
  • Table 10 The activity of phage isolates on HEK cells is dependent upon TLR4. The positive phage isolates identified in Table 9 were tested on HEK:Null cells. "Isolate OD” refers to the average of the duplicate OD values from each isolate. "Avg Control OD +/- S.D.” shows the sample average and standard deviation from the plate on which the corresponding phage isolate was tested. Note that each isolate has an average value that is -not greater than 2 standard deviations above the plate average, indicating that these isolates do not activate HEK:NuH cells.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne de nouveaux ligands polypeptidiques pour récepteur de type Toll 4 (TLR4). Ces nouveaux ligands polypeptidiques modulent la signalisation de TLR4, régulant ainsi la réponse immunitaire innée. L'invention concerne des procédés permettant de moduler la signalisation de TLR4 à l'aide desdits ligands de TLR4 polypeptidiques. L'invention concerne également des vaccins comprenant les nouveaux ligands de TLR4 polypeptidiques et un antigène. Elle concerne enfin des procédés permettant de stimuler une réponse immunitaire au moyen de ces ligands de TLR4 polypeptidiques et de ces vaccins.
PCT/US2006/042051 2005-10-28 2006-10-27 Ligands polypeptidiques pour recepteur de type toll 4 (tlr4) WO2007053455A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73159505P 2005-10-28 2005-10-28
US60/731,595 2005-10-28

Publications (2)

Publication Number Publication Date
WO2007053455A2 true WO2007053455A2 (fr) 2007-05-10
WO2007053455A3 WO2007053455A3 (fr) 2007-06-14

Family

ID=38006399

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/042051 WO2007053455A2 (fr) 2005-10-28 2006-10-27 Ligands polypeptidiques pour recepteur de type toll 4 (tlr4)

Country Status (2)

Country Link
AR (1) AR056591A1 (fr)
WO (1) WO2007053455A2 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007103322A2 (fr) 2006-03-07 2007-09-13 Vaxinnate Corporation Compositions comprenant de l'hémagglutinine, leurs procédés de fabrication et leurs procédés d'utilisation
US7629135B2 (en) 2006-12-22 2009-12-08 The Board Of Trustees Of The University Of Illinois Toll-like receptor agonists and antagonists and methods of use thereof
WO2013132043A1 (fr) 2012-03-08 2013-09-12 Novartis Ag Vaccins combinés comprenant des agonistes du tlr4
WO2013132041A2 (fr) 2012-03-08 2013-09-12 Novartis Ag Formulations à adjuvant de vaccins de rappel
WO2014037472A1 (fr) 2012-09-06 2014-03-13 Novartis Ag Vaccins combinatoires avec méningococcus de sérogroupe b et d/t/p
WO2014057132A1 (fr) 2012-10-12 2014-04-17 Novartis Ag Antigènes de pertussis acellulaires non réticulés pour leur utilisation dans des vaccins combinés
WO2014118305A1 (fr) 2013-02-01 2014-08-07 Novartis Ag Administration intradermique de compositions immunologiques comprenant des agonistes des récepteurs de type toll
WO2014184683A3 (fr) * 2013-04-26 2015-01-22 Oslo Universitetssykehus Hf Compositions et procédés de ciblage de cellules présentatrices d'antigène
US9132141B2 (en) 2012-03-28 2015-09-15 University Of Maryland, Baltimore Administration of eritoran or pharmaceutically acceptable salts thereof to treat orthomyxovirus infections
EP3701964A1 (fr) * 2016-02-17 2020-09-02 Pepticom Ltd Agonistes et antagonistes peptidiques de l'activation de tlr4
US20210236614A1 (en) * 2018-02-07 2021-08-05 Imugene Limited Vaccine composition and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214272A1 (en) * 1999-05-06 2004-10-28 La Rosa Thomas J Nucleic acid molecules and other molecules associated with plants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214272A1 (en) * 1999-05-06 2004-10-28 La Rosa Thomas J Nucleic acid molecules and other molecules associated with plants

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BALDRIDGE J.R. ET AL.: 'Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents' EXPERT OPINION ON. BIO. THER. vol. 4, no. 7, July 2004, pages 1129 - 1138, XP008082206 *
DATABASE GEMBANK AAF95396, 03 August 2000 HEIDELBERG J.F.: 'DNA sequence of both chromosomes of the cholera pathogen Vibrio cholerae', XP003014127 & NATURE vol. 406, no. 6795, pages 477 - 483 *
RYAN E.T. ET AL.: 'Cholera vaccines' CLINICAL INFECTIOUS DISEASES vol. 31, 2000, pages 561 - 565, XP002343357 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007103322A2 (fr) 2006-03-07 2007-09-13 Vaxinnate Corporation Compositions comprenant de l'hémagglutinine, leurs procédés de fabrication et leurs procédés d'utilisation
US7629135B2 (en) 2006-12-22 2009-12-08 The Board Of Trustees Of The University Of Illinois Toll-like receptor agonists and antagonists and methods of use thereof
WO2013132043A1 (fr) 2012-03-08 2013-09-12 Novartis Ag Vaccins combinés comprenant des agonistes du tlr4
WO2013132041A2 (fr) 2012-03-08 2013-09-12 Novartis Ag Formulations à adjuvant de vaccins de rappel
US9132141B2 (en) 2012-03-28 2015-09-15 University Of Maryland, Baltimore Administration of eritoran or pharmaceutically acceptable salts thereof to treat orthomyxovirus infections
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
WO2014037472A1 (fr) 2012-09-06 2014-03-13 Novartis Ag Vaccins combinatoires avec méningococcus de sérogroupe b et d/t/p
WO2014057132A1 (fr) 2012-10-12 2014-04-17 Novartis Ag Antigènes de pertussis acellulaires non réticulés pour leur utilisation dans des vaccins combinés
EP3620172A1 (fr) 2012-10-12 2020-03-11 GlaxoSmithKline Biologicals SA Antigènes de pertussis acellulaires non réticulés pour leur utilisation dans des vaccins combinés
WO2014118305A1 (fr) 2013-02-01 2014-08-07 Novartis Ag Administration intradermique de compositions immunologiques comprenant des agonistes des récepteurs de type toll
US9827190B2 (en) 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
WO2014184683A3 (fr) * 2013-04-26 2015-01-22 Oslo Universitetssykehus Hf Compositions et procédés de ciblage de cellules présentatrices d'antigène
EP3701964A1 (fr) * 2016-02-17 2020-09-02 Pepticom Ltd Agonistes et antagonistes peptidiques de l'activation de tlr4
US11155578B2 (en) 2016-02-17 2021-10-26 Pepticom Ltd. Peptide agonists and antagonists of TLR4 activation
US20210236614A1 (en) * 2018-02-07 2021-08-05 Imugene Limited Vaccine composition and uses thereof

Also Published As

Publication number Publication date
WO2007053455A3 (fr) 2007-06-14
AR056591A1 (es) 2007-10-10

Similar Documents

Publication Publication Date Title
US20090028889A1 (en) Novel Polypeptide Ligands For Toll-Like Receptor 2 (TLR2)
WO2007053455A2 (fr) Ligands polypeptidiques pour recepteur de type toll 4 (tlr4)
US20090068224A1 (en) Method to identify polypeptide toll-like receptor (tlr) ligands
JP5800928B2 (ja) 新規ペプチド化合物
RU2721574C2 (ru) Вакцинная композиция против злокачественной опухоли
CA2661651A1 (fr) Immunogenes inducteurs de la production de lymphocytes t cytotoxiques pour la prevention, le traitement et le diagnostic du cancer
KR20000005429A (ko) 비수지성 주쇄 펩티드 담체
KR20120054644A (ko) 이량체화 펩티드
RU2714117C2 (ru) Пептид, полученный из gpc3, фармацевтическая композиция для лечения или предотвращения рака с его использованием, индуктор иммунитета и способ получения антиген-презентирующих клеток
JP2008538901A (ja) 癌胎児性抗原未熟型ラミニンレセプタータンパク質から誘導されるｈｌａ−２提示ｔ細胞エピトープの同定およびそれらの使用
US20040146519A1 (en) Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions
AU2003213140A1 (en) Compositions and compounds for use as molecular adjuvant for a nicotine vaccine
DK2742133T3 (en) MPHOSPH1 PEPTIDES AND VACCINES CONTAINING THESE
JP2014519311A (ja) Ｓｅｍａ５ｂペプチドおよびそれを含むワクチン
CA2393339A1 (fr) Declenchement de reponses immunitaires cellulaires a mage2/3 au moyen de compositions de peptides et d'acides nucleiques
WO2007053428A2 (fr) Procede d'identification de ligands du recepteur de type toll polypeptidiques
JP2014506114A (ja) Ｔｏｍｍ３４ペプチドおよびそれを含むワクチン
US20040048790A1 (en) Inducing cellular immune responses to p53 using peptide and nucleic acid compositions
JP2003512388A (ja) 免疫治療で使用される修飾ペプチドおよびペプチド模倣体
KR20170040315A (ko) Cdca1-유래 펩티드 및 이를 포함하는 백신
KR20170030649A (ko) Urlc10-유래 펩티드 및 이를 포함하는 백신
JP2005537325A (ja) 細胞活性モジュレーション方法およびそこで使用される分子
AU4111999A (en) Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06826902

Country of ref document: EP

Kind code of ref document: A2